<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Malaria: Epidemiology, prevention, and control</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Malaria: Epidemiology, prevention, and control</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Malaria: Epidemiology, prevention, and control</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kim A Lindblade, PhD, MPH, FASTMH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Johanna Daily, MD, MSc</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Edward T Ryan, MD, DTMH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 22, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Malaria is transmitted throughout most of the tropics; ongoing transmission occurs in 84 countries and territories [<a href="#rid1">1</a>]. In 2023, the World Health Organization (WHO) reported 247 million cases (up from 245 million in 2020) and 619 thousand deaths (down from 625,000 in 2020) due to malaria [<a href="#rid2">2</a>]. </p><p>The annual number of malaria cases decreased steadily between 2000 and 2015 but thereafter, malaria cases have increased. Between 2019 and 2021 the number of malaria cases increased by 13 million, significantly more than any inter-annual increase since 2000. This increase is attributed largely to interruption of services due to the coronavirus disease 2019 (COVID-19) pandemic [<a href="#rid3">3</a>]. The COVID-19 pandemic was also associated with an estimated increase of 63,000 deaths attributed to malaria between 2019 and 2021 [<a href="#rid4">4</a>]. </p><p>In 2019, WHO revised its approach to calculating the number of deaths attributed to malaria. With the revised WHO calculation, malaria accounts globally for 7.8 percent of the fraction of deaths in children aged less than 5 years (rather than 4.8 percent as reported previously).</p><p>The emergence of <em>Plasmodium falciparum</em> artemisinin partial resistance in the African region is of great concern [<a href="#rid4">4</a>], as are increasing reports of <em>Anopheles</em> spp resistance to pyrethroid insecticides [<a href="#rid2">2</a>]. The expansion of the range of an Asian malaria vector, <em>An. stephensi</em>, to the African continent has prompted WHO to launch a new initiative aimed at stopping its spread. An additional threat to malaria control and elimination is the continued increase in parasites that have lost the genes that express proteins detected by rapid diagnostic tests [<a href="#rid4">4</a>]. </p><p>In 2021, the WHO recommended the first malaria vaccine, RTS,S/AS01, for use in children who reside in regions with moderate to high <em>P. falciparum</em> transmission [<a href="#rid3">3</a>]. In 2023, 12 African countries (three countries that conducted a pilot introduction of the vaccine plus nine more nations) received approval to deploy the vaccine through their routine immunization programs [<a href="#rid5">5</a>]. WHO recommendation of a second malaria vaccine (R21/Matrix-M™) in 2023 is expected to expand available supply. </p><p>In addition to these positive developments, an increasing number of countries have become malaria free and received WHO certification of malaria elimination; these include El Salvador (2021), China (2021), Azerbaijan (2023), Tajikistan (2023), and Belize (2023) [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H2368867023"><span class="h2">Transmission</span><span class="headingEndMark"> — </span>The malaria parasite is transmitted primarily via the bite of an infected female <em>Anopheles</em> spp mosquito, which occurs mainly between dusk and dawn. Other rare routes of transmission include congenitally acquired disease, via blood transfusion, sharing of contaminated needles, organ transplantation, and nosocomial transmission [<a href="#rid7">7-9</a>]. </p><p>The entomologic inoculation rate (EIR; the number of infectious female anopheline bites per person per year) is a term used to indicate transmission intensity. While there are seasonal and geographic differences, an EIR of &lt;10/year is low transmission, 10 to 49/year is intermediate, and ≥50/year is a high transmission area. In general, the higher the EIR, the greater the burden of malaria, particularly in young children [<a href="#rid10">10</a>].</p><p>The principal determinants of the epidemiology of malaria are the number (density), the human-biting habits (indoors or outdoors), and the longevity of the female anopheline vectors. The transmission of malaria is directly proportional to the density of the vector, the square of the number of human bites per day per mosquito, and the 10<sup>th</sup> power of the probability of the mosquito's survival for one day [<a href="#rid11">11,12</a>]. </p><p>Mosquito longevity is particularly important, because the portion of the parasite's life cycle that takes place within the mosquito (sporogony; from gametocyte ingestion to subsequent inoculation) lasts for 8 to 30 days, depending on the species of <em>Plasmodium</em> and ambient temperature; thus, to transmit malaria, the mosquito must survive for &gt;10 days. The most effective mosquito vectors of malaria are those such as <em>Anopheles gambiae</em> in Africa, which are long lived, occur in high densities in tropical climates, breed readily, rest and bite within dwellings, and bite humans in preference to other animals.</p><p class="headingAnchor" id="H1443490973"><span class="h2">Geographic burden</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Worldwide</strong> – Over 95 percent of the burden occurs in the WHO defined African region, followed by 2 percent each in the Southeast Asian and Eastern Mediterranean regions, with the American and Western Pacific regions contributing the remainder. There are no countries in the European region with ongoing malaria transmission.</p><p></p><p class="bulletIndent1">Twenty-nine countries account for 96 percent of cases; Nigeria (27 percent), the Democratic Republic of Congo (12 percent), Uganda (5 percent), Mozambique (4 percent), and Angola and Burkina Faso (each 3 percent) account for 55 percent of all cases globally. </p><p></p><p class="bulletIndent1">Deaths due to malaria continue to occur mainly among African children &lt;5 years of age [<a href="#rid2">2</a>], who make up 76 percent of global malaria deaths. </p><p></p><p class="bulletIndent1">Ascertainment of cases and deaths is the biggest challenge to understanding malaria control program success. Among 55 countries where the burden was estimated, 31 countries had a malaria reporting rate of less than 50 percent; this includes the high burden countries of Nigeria, the Democratic Republic of Congo, and India [<a href="#rid3">3</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Regional and seasonal variability</strong> – The epidemiology of malaria may vary considerably even within relatively small geographic areas. Traditionally, the intensity of transmission has been defined in terms of parasitemia rates or palpable spleen rates in children two to nine years of age as hypoendemic (≤10 percent), mesoendemic (11 to 50 percent), hyperendemic (51 to 74 percent), and holoendemic (≥75 percent). </p><p></p><p class="bulletIndent2">Subsequently, WHO has used annual malaria incidence rates and parasite prevalence to broadly classify areas as very low (&lt;100 cases per 1000 population or &lt;1 percent parasite prevalence), low (100 to 250 cases per 1000 or 1 to 10 percent prevalence), moderate (250 to 450 cases per 1000 or 10 to 35 percent prevalence) or high (&gt;450 cases per 1000 or &gt;35 percent prevalence) [<a href="#rid13">13</a>]. </p><p></p><p class="bulletIndent2">In areas with high levels of <em>P. falciparum</em> transmission (eg, certain regions of tropical Africa or coastal New Guinea where there is intense transmission), people may receive more than one infectious mosquito bite per day and are infected repeatedly throughout their lives. In such settings with intense transmission, morbidity and mortality due to malaria during early childhood are considerable. By the time residents reach adulthood, most infections are asymptomatic due to host immunity gained from frequent exposure. In contrast, in areas where transmission is low to very low, full protective immunity is not acquired, and symptomatic disease occurs at all ages.</p><p></p><p class="bulletIndent2">Relatively constant, year-round infection is termed perennial transmission; occurrence of cases in just a few months of the year is termed seasonal transmission. In areas where population immunity to malaria is low, malaria behaves like an epidemic disease, particularly in areas with highly seasonal transmission such as northern India (Rajasthan), Afghanistan, Iraq, Turkey, Ethiopia, Eritrea, Burundi, southern Africa (Botswana, Mozambique, Namibia, South Africa, Swaziland, Zimbabwe), and Madagascar. An epidemic can develop if there are changes in environmental, economic, or social conditions, such as heavy rains following drought or migrations (usually of refugees or workers) from a non-malarious region to an area of high transmission; a breakdown in malaria control and prevention services can intensify epidemic conditions. This situation usually results in considerable morbidity and mortality among all age groups [<a href="#rid14">14</a>]. .</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>United States</strong> – Malaria transmission was eliminated in the United States in the mid-1950s. However, malaria continues to be acquired by travelers to malaria-affected areas and approximately 2000 imported cases of malaria are reported in the United States each year. Most of the cases imported to the United States come from Africa (85 percent) with the majority from West Africa (70 percent). Overall, <em>P. falciparum</em> caused 70 percent of cases followed by <em>P. vivax</em> (10 percent) and <em>P. ovale</em> (5 percent) in 2018. Virtually all patients became ill within three months of returning to the United States. Of the 95 percent who did not take prophylaxis properly, 25 percent took none at all. Severe illness occurred in 14 percent of patients, and seven persons died [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1">In 2023, nine locally acquired cases of <em>P. vivax</em> malaria were reported in Florida and Texas [<a href="#rid16">16</a>]. A single case of locally acquired <em>P. falciparum</em> was identified in Maryland [<a href="#rid17">17,18</a>]. These were the first locally acquired cases of malaria since 2003.</p><p></p><p class="headingAnchor" id="H415213477"><span class="h2">Distribution by species</span><span class="headingEndMark"> — </span>Malaria occurs throughout most of the tropical regions of the world, with <em>P. falciparum</em> causing the largest burden of disease, followed by <em>P. vivax</em>  (<a class="graphic graphic_figure graphicRef72797 graphicRef103385 graphicRef142995" href="/d/graphic/72797.html" rel="external">figure 1A-C</a>) [<a href="#rid19">19</a>]. <em>P. falciparum</em> predominates in sub-Saharan Africa, New Guinea, and Hispaniola (Haiti and the Dominican Republic); <em>P. vivax</em> is much more common in the Americas and the western Pacific. The prevalence of these two species was approximately equal in the Indian subcontinent, eastern Asia, and Oceania in the late 1900s but <em>P. falciparum</em> is now responsible for two-thirds of cases  (<a class="graphic graphic_table graphicRef56132" href="/d/graphic/56132.html" rel="external">table 1</a>) [<a href="#rid20">20-22</a>]. </p><p><em>P. malariae</em> is uncommon but is found in most malaria-affected areas, especially in sub-Saharan Africa. <em>P. ovale</em>, less common, is relatively unusual outside of Africa and comprises &lt;1 percent of isolates. <em>P. knowlesi</em>, similar morphologically to <em>P. malariae</em>, has been identified by molecular methods in patients in Malaysia, the Philippines, Thailand, and Myanmar [<a href="#rid23">23</a>]; this is a zoonotic infection and there is no evidence of sustained transmission of this species between humans (ie, a monkey reservoir is required to infect mosquitoes) [<a href="#rid24">24</a>]. <em>P. simium</em> is a malaria species resembling <em>P. vivax</em> that occurs in primates; in contrast to <em>P. knowlesi</em>, it has been shown to be transmitted between humans in Brazil [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/d/html/5706.html" rel="external">"Non-falciparum malaria: P. vivax, P. ovale, and P. malariae"</a>.)</p><p class="headingAnchor" id="H23982632"><span class="h2">Surveillance</span><span class="headingEndMark"> — </span>Clinical, epidemiologic, entomologic, and parasitologic surveillance of malaria is required to determine the effect of malaria control and elimination programs. Depending on resources and the burden of malaria disease, emphasis should be on detecting clinical manifestations of illness in public and private hospitals and health units initially (passive surveillance). As transmission is reduced, active detection of malaria infections house by house (active surveillance) may become important in areas without access to passive surveillance or with hard-to-reach or at risk populations [<a href="#rid26">26</a>]. Modern information technologies (eg, cell phones, hand-held data entry devices, computerized reporting, feedback bulletins) will be necessary to assure prompt and accurate sharing of information. Surveillance of morbidity, mortality, disability, drug, and insecticide resistance and of commodities including quality of drugs, nets, and insecticides will be the key to malaria elimination and ultimately eradication [<a href="#rid27">27</a>]; additionally, provider practices and patient compliance require monitoring and evaluation [<a href="#rid28">28</a>].</p><p>An article summarizing nearly 27,000 malaria parasite prevalence surveys in Africa indicated that there was a 40 percent reduction in the prevalence of malaria infection across most of sub-Saharan Africa in the decade 2000 to 2015 [<a href="#rid29">29-31</a>]. Interventions averted 1.7 billion malaria cases between 2000 and 2020 [<a href="#rid2">2</a>]. Reductions in the malaria burden, while encouraging, were not sustained; since 2016, the number of malaria cases and deaths have increased.</p><p>An analysis of deaths due to malaria in Africa noted highest mortality rates and lowest coverage of bed nets and antimalarial drug use in Nigeria, Angola, Cameroon, Central African Republic, Democratic Republic of Congo, Guinea, and Equatorial Guinea [<a href="#rid32">32</a>].</p><p>A review of antimalarial drug quality in Asia and Africa showed an alarming prevalence of counterfeit drugs on the shelves of pharmacies in multiple countries [<a href="#rid33">33</a>]; up to 36 percent of antimalarial drugs and 43 percent of the artemisinin combination drugs were falsified. This criminal behavior requires more attention, including definition of the problem locally, scientific and technological means to identify rapidly poor quality drugs and other commodities (eg, diagnostic tests), regulatory action, and national and international laws [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H3"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>To consider interventions to reduce the burden or transmission of malaria, it is important to define the goals of control, elimination, and eradication. Control is reduction of disease incidence and prevalence to levels that do not pose a threat to public health or that are acceptable to a community. Elimination is reduction of incidence and transmission to zero in humans in a defined geographic area. Eradication is global elimination of human disease. In all instances, a surveillance system that could detect, respond to, and report malaria cases and infections promptly is essential.</p><p>Despite progress, one problem with the Millennium Development Goals (MDGs; now Sustainable Development Goals [SDGs], which aimed to reduce malaria incidence and prevalence by 75 percent by 2015 compared with 2000) is that baseline epidemiologic information for malaria is incomplete in most malaria-affected countries. Following successful elimination, ongoing rigorous surveillance is needed to identify imported cases, which must be detected, treated, and contained promptly to prevent reestablishment of transmission. </p><p>In the past, clinical diagnosis alone, based on signs and symptoms, has been used in most malaria-affected African areas for diagnosing and recording malaria cases, contributing to substantial imprecisions. Training and supervision of clinicians in proper diagnosis of suspected malaria remain the most important keys to effective case management and surveillance [<a href="#rid35">35</a>]. Microscopic confirmation of malaria, the historic "gold standard," is frequently delayed and inaccurate; hence, rapid diagnostic tests (RDT) are being used with increasing frequency especially in Africa. Advantages of RDTs include improved diagnosis, rapidity, and more rational use of antimalarial drugs. Diagnosis of malaria is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5707.html" rel="external">"Laboratory tools for diagnosis of malaria"</a>.)</p><p>With the Bill and Melinda Gates challenge in 2007 to eradicate malaria, there is increasing enthusiasm to reassess older control methods and develop and evaluate new ones through research. The approach to malaria eradication proposed by the WHO in 1955 includes the preparatory, attack, consolidation, and maintenance phases  (<a class="graphic graphic_figure graphicRef79347" href="/d/graphic/79347.html" rel="external">figure 2</a>). Progression between these phases depends on reducing the incidence of parasitemia in the population, which requires an understanding of the intrinsic and extrinsic factors of malaria transmission. Intrinsic factors include the relationships between human, parasite, and mosquito; extrinsic factors include the environment, socioeconomic milieu, and control initiatives [<a href="#rid36">36</a>]. The most important epidemiological criterion for moving from the attack to the consolidation phase of malaria eradication (in which surveillance is the key) is annual incidence of &lt;0.1 infections/1000 persons (1 case per 10,000 population) [<a href="#rid11">11</a>].</p><p>Research in support of malaria eradication is a major component of the current global effort. The malaria eradication research agenda has been defined by task forces addressing specific themes [<a href="#rid37">37,38</a>].</p><p class="headingAnchor" id="H4"><span class="h1">ELEMENTS FOR MALARIA CONTROL AND ELIMINATION</span><span class="headingEndMark"> — </span>Strategies to reduce and interrupt malaria transmission include effective deployment of antimalarial drugs, personal mosquito protection, mosquito vector control, and research (including vaccine development) [<a href="#rid11">11</a>]. Optimal malaria control (eg, leading to elimination) using these tools requires the following elements of the updated WHO Global Technical Strategy for Malaria 2016 to 2030 [<a href="#rid39">39</a>]. In addition to national and community ownership of malaria programs and innovation in tools and implementation, the technical foci are:</p><p class="bulletIndent1"><span class="glyph">●</span>Maximizing the effectiveness of vector control, including adequate entomological surveillance, management of insecticide resistance and identification of solutions to residual transmission</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Expanding chemoprevention to vulnerable groups</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ensuring diagnostic confirmation of all suspected malaria cases, including at the community level, and effective treatment of all confirmed cases, including management of antimalarial drug resistance</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Strengthening surveillance of malaria to provide data needed for all technical areas</p><p></p><p>In 2021, there were 84 countries with ongoing malaria transmission, compared with 108 in 2000 [<a href="#rid2">2</a>]. Since 2000, there have been 15 countries certified malaria-free while 11 more have attained three consecutive years of zero indigenous cases. WHO focuses most efforts on the 11 highest burden countries that make up the 'High Burden – High Impact' initiative catalyzed by WHO and the RBM Partnership to End Malaria [<a href="#rid40">40</a>], as well as the 25 countries closest to elimination that make up the E-2025.</p><p class="headingAnchor" id="H1659808458"><span class="h1">HOST PROTECTION</span></p><p class="headingAnchor" id="H3439232548"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Tools for human protection from malaria infection include protection from mosquito bites, chemoprevention, and vaccination. It is uncertain whether combining these interventions may confer increased protection. </p><p>In one trial including more than 6000 children age 5 to 17 months in Burkina Faso and Mali (regions of seasonal transmission) randomly assigned to receive seasonal vaccination (primary three-dose series of RTS,S/ASO1 vaccine, followed by two annual boosters), chemoprevention (four monthly courses of sulfadoxine-pyrimethamine and amodiaquine each year), or both, a lower three-year incidence of uncomplicated malaria, severe malaria, and death from malaria was observed among those who received both interventions rather than either alone [<a href="#rid41">41</a>]. The protective efficacy of both interventions compared with chemoprevention alone against these outcomes (calculated as [1-hazard ratio] x 100) was 62.8 percent (95% CI 58.4-66.8), 70.5 percent (95% CI 41.9-85.0), and 72.9 percent (95% CI 2.9-92.4), respectively; the protective efficacy of both interventions compared with vaccine alone was 59.6 percent (95% CI 54.7-64.0), 70.6 percent (95% CI 42.3-85.0), and 75.3 percent (95% CI 12.5-93.0), respectively. These findings support a promising approach to reducing the burden of disease in areas with seasonal transmission of malaria; optimization of delivery to perennial transmission areas are needed.</p><p class="headingAnchor" id="H145549092"><span class="h2">Protection from mosquito bites</span></p><p class="headingAnchor" id="H2709824157"><span class="h3">Repellents</span><span class="headingEndMark"> — </span>Repellents applied to exposed skin may be used to protect against mosquito bites. Effective repellents include synthetic preparations such as DEET (N,N-diethyl-m-toluamide), Picardin (KBR3023), and IR 3535, as well as PMD (P-MENTHANE-3,8-DIOL), which is derived from lemon eucalyptus [<a href="#rid42">42</a>]. For maximal protection against mosquitoes, DEET is preferable over other agents. Selection and use of mosquito repellents are discussed separately. (See  <a class="medical medical_review" href="/d/html/4085.html" rel="external">"Prevention of arthropod and insect bites: Repellents and other measures"</a>.)</p><p>The efficacy of mosquito repellents for protection against malaria is variable depending on the mosquito vector. Repellents are most effective in areas where vectors feed in the early evening (as with many South American and Asian vectors) rather than later in the night (as with African vectors such as <em>An. gambiae</em>). Repellents may also be more effective in regions with zoophilic vectors as in the Americas and south Asia (where mosquitoes may be diverted from a repellent-treated person to an animal) than in regions with anthropophilic vectors (Africa). This was illustrated in a cluster-randomized study of 4008 participants in rural Bolivia, where the principal vector is <em>Anopheles darlingi</em> [<a href="#rid43">43</a>]. All participants slept under treated nets; one group also used a plant-based insect repellent each evening, while a second group used placebo. Rates of <em>P. vivax</em> malaria episodes were reduced by 80 percent. A protective but not significant effect was observed for <em>P. falciparum</em> as the number of cases was small.</p><p>Repellents have also been protective against malaria in refugee camps on the Pakistan-Afghan border; in this region, the main vectors of malaria are <em>Anopheles stephensi</em>, <em>An. culicifacies</em>, <em>An. pulcherrimus,</em> and <em>An. nigerrimus </em>[<a href="#rid44">44</a>]. Among 127 families randomized to receive repellent soap (20% DEET/0.5% <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">permethrin</a>) or placebo, fewer cases of <em>P. falciparum</em> malaria were observed among those using repellent soap (3.7 versus 8.9 percent). There was no effect against <em>P. vivax</em> malaria.</p><p>In regions where vectors feed in the middle of the night, repellents might not increase the degree of protection afforded by use of insecticide-treated nets alone; this requires further evaluation.</p><p class="headingAnchor" id="H2959125221"><span class="h3">Insecticide-treated nets (ITNs)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benefit </strong>− Use of ITNs is an important tool for malaria control. In a 2018 systematic review including 23 trials enrolling more than 275,000 adults and children between 1987 and 2001, use of ITNs was associated with a reduction of child mortality from all causes by 17 percent (rate ratio 0.83, 95% CI 0.77 to 0.89) [<a href="#rid45">45</a>]. In addition, a 44 percent reduction in the incidence of severe malaria episodes was observed among those who used ITNs (rate ratio 0.56, 95% CI 0.38 to 0.82). </p><p></p><p class="bulletIndent1">Thus far use of pyrethroid-impregnated nets does not appear to have toxicity for humans [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to selection </strong>− Use of ITNs treated with pyrethroids has been an important tool for malaria control since the 1990s; however, pyrethroid resistance among mosquitoes has become widespread. Subsequently, new ITNs have been developed that contain a chemical (piperonyl-butoxide, PBO) that renders some pyrethroid-resistant mosquitoes susceptible to the insecticide. Additionally, next generation ITNs that contain a second active ingredient (AI, either a second insecticide or an insect growth regulator) in addition to a pyrethroid insecticide have received WHO recommendations for use in areas with pyrethroid resistance.</p><p></p><p class="bulletIndent1">In areas where pyrethroids remains effective, WHO continues to recommend use of pyrethroid-only ITNs. In areas where the main malaria vector(s) exhibit confirmed pyrethroid resistance, WHO guidelines favor use of one of the ITNs intended for areas with pyrethroid resistance. [<a href="#rid46">46</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Insecticide formulations</strong> − Pyrethroids remain the principal insecticide class on WHO-recommended ITNs. PBO-ITNs add the chemical synergist PBO to the net to render resistant mosquitoes susceptible to pyrethroids. Next-generation dual AI nets include pyrethroids plus chlorfenapyr, an insecticide, or pyriproxyfen, an insect growth regulator. Combining pyrethroids with a second AI with a different mode of action helps to overcome pyrethroid resistance; additional dual AI nets currently are being evaluated by WHO. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pyrethroids</strong> − Pyrethroids have been the mainstay insecticide class for ITN treatment since the late 1990s. However, pyrethroid resistance among mosquitoes has become widespread; failure of pyrethroid-based ITNs has been reported in West Africa and elsewhere [<a href="#rid47">47-50</a>]. </p><p></p><p class="bulletIndent2">Laboratory detection of resistance genes may or may not correlate with epidemiologic observations. Genes for pyrethroid resistance were first demonstrated among mosquito vectors in the Ivory Coast; however, pyrethroid-based ITNs remained effective for preventing malaria in this region [<a href="#rid51">51</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Piperonyl butoxide (PBO)</strong> – Emergence of pyrethroid resistance has prompted development of ITNs incorporating a chemical synergist, PBO [<a href="#rid52">52,53</a>]. PBO inhibits the metabolic enzymes found in resistant mosquitoes that detoxify insecticides before they reach their target within the mosquito. As a result, mosquitoes that encounter the PBO are effectively rendered susceptible to pyrethroids. PBO-treated nets are not expected to confer any additional benefit in areas where the main malaria vectors are susceptible to pyrethroids.</p><p></p><p class="bulletIndent2">In a 2020 cluster-randomized including more than 100 subdistricts in Uganda with high pyrethroid resistance, use of PBO-treated LLINs was associated with reduced parasite prevalence compared with conventional LLINs at 18 months (12 versus 14 percent; prevalence ratio 0.84, 95% CI 0.72-0.98) [<a href="#rid54">54</a>]. </p><p></p><p class="bulletIndent2">Similarly, in a 2018 cluster-randomized trial among more than 3600 children in Tanzania, the malaria prevalence after was lower among those who used PBO-treated nets than among those who used pyrethroid-treated nets (follow-up 9 months; 29 versus 42 percent; odds ratio 0.37, 95% CI 0.21-0.65); use of indoor residual spraying was not associated with additional benefit [<a href="#rid55">55</a>]. </p><p></p><p class="bulletIndent2">However, in a 2022 cluster-randomized study including more than 39,000 households in a Tanzania region with high prevalence of pyrethroid resistance, there was no difference in malaria prevalence among children who used PBO-treated nets and children who used pyrethroid-treated nets (adjusted odds ratio 0.99, 95% CI 0.67-1.45) [<a href="#rid56">56</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chlorfenapyr-pyrethroid</strong> – Chlorfenapyr is an insecticide from the pyrrole class. Insecticides in this class disrupt energy production in the mosquito, leading to death. Chlorfenapyr-pyrethroid ITNs have been evaluated in two large trials:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a 2023 cluster-randomized study including more than 53,000 households in Benin, clusters were randomly assigned to receive ITNs containing either chlorfenapyr-pyrethroid, pyriproxyfen-pyrethroid, or pyrethroid only [<a href="#rid57">57</a>]. More than two years after ITN distribution, lower malaria incidence was observed in clusters where ITNs treated with chlorfenapyr-pyrethroid were used (rather than ITNs treated with pyrethroid only; incidence 0.56 versus 1.03 cases per child-year; hazard ratio 0.54, 95% CI 0.42-0.70). Pyriproxyfen-pyrethroid ITNs conferred protection similar to pyrethroid-only ITNs (incidence 0.84 cases per child-year; hazard ratio 0.86, 95% CI 0.65-1.14). </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a 2022 cluster-randomized study including more than 39,000 households in a Tanzania region with high prevalence of pyrethroid resistance, lower malaria incidence among children age 6 months to 10 years was observed in clusters where nets treated with chlorfenapyr-pyrethroid were used (rather than nets treated with pyrethroid only; incidence rate ratio 0.56, 95% CI 0.37-0.86) [<a href="#rid56">56</a>]. Similarly, at two-year follow-up, malaria prevalence was lower among children who used pyrethroid-chlorfenapyr ITNs (25.6 versus 45.8 percent; odds ratio 0.45, 95% CI 0.30-0.67). The cost per disability-adjusted life-year averted with pyrethroid-chlorfenapyr ITNs was below plausible cost-effectiveness thresholds. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pyriproxyfen-pyrethroid </strong>− Pyriproxyfen is an insect growth regulator that effectively sterilizes female mosquitoes. In the 2022 and 2023 trials of chlorfenapyr-pyrethroid ITNs described above, there was no difference in malaria prevalence among children who used pyriproxyfen-treated nets and those who used pyrethroid-only nets [<a href="#rid56">56,57</a>]. </p><p></p><p class="bulletIndent2">These findings differ from those of an earlier randomized trial in 2018 in Burkina Faso (an area of intense malaria transmission and high pyrethroid resistance) including more than 4000 children &lt;5 years of age; the likelihood of malaria among children using ITNs treated with pyriproxyfen-pyrethroid was lower than among children using ITNs treated with <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">permethrin</a> only (1.5 versus 2.0 episodes per child-year; incidence rate ratio 0.88, 95% CI 0.77-0.99) [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Local ITN implementation</strong> − Community health education is essential for correct ITN installation, maintenance, and timing of use. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>ITN durability</strong> – Long-lasting ITNs must demonstrate efficacy after 20 washes and manufacturer claims may suggest that ITNs remain effective for three years or longer. However, multiple field studies have demonstrated that fewer than half of ITNs remain functional three years after distribution [<a href="#rid59">59</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ITN use does not appear to delay acquisition of natural immunity against malaria</strong> − It has been postulated that ITN use might delay acquisition of natural immunity against malaria, with increased risk for illness at older ages; however, this does not appear to be the case. In a long-term cohort study of ITN use including more than 6700 individuals during early childhood in rural Tanzania between 1998 and 2003, follow-up on vital status in 2019 was obtained for 89 percent of participants [<a href="#rid60">60</a>]. Reported use of ITN at more than half of the early-life study visits was associated with a reduced risk of death from early childhood to adulthood (hazard ratio 0.57, 95% CI 0.45-0.72). Although most deaths occurred prior to age 5, that level of ITN use was still associated with a trend towards lower mortality between five years and adulthood (hazard ratio 0.93, 95% CI 0.58-1.49). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of ITNs with indoor residual spraying</strong> − Methods of interrupting malaria transmission must be considered carefully and evaluated both individually and in combination. A systematic review of adding IRS to areas where ITNs are already deployed found no additional benefit when IRS used a pyrethroid-like insecticide. However, IRS using non-pyrethroid insecticides was found to reduce malaria prevalence, although it did not have an effect on malaria incidence [<a href="#rid61">61</a>]. WHO recommends against co-deployment of ITNs and IRS and suggests that priority should be given to providing better coverage of one or the other rather than trying to implement both [<a href="#rid62">62</a>]. </p><p></p><p class="headingAnchor" id="H1311674551"><span class="h2">Preventive chemotherapies</span></p><p class="headingAnchor" id="H29018577"><span class="h3">Specific target groups</span></p><p class="headingAnchor" id="H1873500373"><span class="h4">Infants and children</span></p><p class="headingAnchor" id="H17275755"><span class="h5">Children in areas with perennial transmission</span><span class="headingEndMark"> — </span>WHO recommends administration of a full treatment course of an antimalarial medicine at predefined intervals to children in moderate to high transmission areas where malaria occurs year-round. Formerly known as intermittent preventive treatment in infants (IPTi), the new strategy is referred to as 'perennial malaria chemoprevention' (PMC) [<a href="#rid62">62</a>]. PMC strategies target the age groups of children at increased risk of severe malaria or death, which may include children up to 24 months. Countries are encouraged to adapt the medicine and timing and number of doses to local conditions; various countries in sub-Saharan Africa are working to evaluate different models of PMC. [<a href="#rid63">63</a>].</p><p>PMC with slowly eliminated antimalarials appears to be effective for reducing episodes of malaria in infants and does not appear to affect serologic response to routine vaccinations [<a href="#rid64">64</a>]. A 2021 Cochrane review of IPTi using various antimalarial medicines included 12 trials and more than 19,000 infants in sub-Saharan Africa. IPTi was associated with a 30 percent reduction in the incidence of clinical malaria infection (rate ratio 0.70, 95% CI 0.62-0.80; 10,602 participants) [<a href="#rid65">65</a>]. The effect of IPTi with SP appeared to attenuate over time; trials conducted after 2009 demonstrated little or no effect when SP was used although trials with ACTs showed more benefit.</p><p>SP has been used safely for chemoprevention in Africa for several decades; while ACTs have been proven effective in clinical studies, evidence is limited on their safety, efficacy and cost-effectiveness [<a href="#rid62">62</a>]. </p><p class="headingAnchor" id="H1399091032"><span class="h5">Children in areas with seasonal transmission</span><span class="headingEndMark"> — </span>Implementation of seasonal malaria chemoprevention (SMC) among children in six West African countries with high malaria transmission has been associated with marked decrease in morbidity and mortality [<a href="#rid66">66</a>]. In a case-control study including 2185 cases of confirmed malaria and 4370 controls during the 2015 and 2016 transmission seasons in Burkina Faso, Chad, the Gambia, Guinea, Mali, Niger, and Nigeria, the pooled estimate of SMC effectiveness in reducing the incidence of clinical malaria within 28 days was 88.2 percent (95% CI 78.7-93.4). SMC was associated with reductions in the number of in-hospital malaria deaths during the high-transmission period in Burkina Faso by 42.4 percent (95% CI 5.9-64.7) and in the Gambia by 56.6 percent (95% CI 28.9-73.5). The estimated reduction in confirmed outpatient malaria cases ranged from 25.5 percent (95% CI 6.1-40.9) in Nigeria to 55.2 percent (95% CI 42.0-65.3) in the Gambia.</p><p>A review of seven trials including more than 12,000 participants noted that IPTc prevented 75 percent of malaria episodes [<a href="#rid67">67</a>]. A subsequent study of SMC in Senegal with AQ-SP among children &lt;10 years noted reduction in malaria incidence (60 percent) and severe malaria (45 percent) [<a href="#rid68">68</a>].</p><p>Addition of <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> to antimalarial agents among children 3 to 59 months of age in Burkina Faso and Mali was not associated with a reduction in mortality [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H3703575014"><span class="h5">Children in areas with perennial or seasonal transmission</span></p><p class="bulletIndent1"><span class="glyph">●</span>IPT may be beneficial among school children [<a href="#rid70">70,71</a>]. In one trial in Uganda, 740 children aged 6 to 14 years were randomly assigned to receive dihydroartemisinin-piperaquine (once a month), dihydroartemisinin-piperaquine (once a school term; 4 treatments over 12 months), or placebo and were followed for 12 months [<a href="#rid70">70</a>]. In the placebo arm, the incidence of malaria was 0.34 episodes per person-year and the prevalence of parasitemia and anemia was 38 and 20 percent, respectively. Monthly IPT reduced the incidence of malaria by 96 percent (95% CI 88-99 percent), the prevalence of asymptomatic parasitemia by 94 percent (95% CI 92-96 percent), and the prevalence of anemia by 40 percent (95% CI 19-56 percent). IPT given once each school term had no significant effect on the incidence of symptomatic malaria or the prevalence of anemia but reduced the prevalence of asymptomatic parasitemia by 54 percent (95% CI 47-60 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The role of IPT during the dry season is uncertain. It has been postulated that subclinical malaria infection during the nontransmission (dry) season is important in maintaining protective immunity and that administering treatment for asymptomatic infection may predispose to more severe infection during the following rainy season. A prospective study of over 600 individuals in a region of seasonal malaria transmission in Mali demonstrated that treatment of asymptomatic infection with <a class="drug drug_general" data-topicid="9066" href="/d/drug information/9066.html" rel="external">artemether-lumefantrine</a> was not associated with increased risk of symptomatic malaria during the following two rainy seasons [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In areas with seasonal flooding, mass drug administration is very effective for reducing malaria. In one study including more than 550 Ugandan children ≤12 years of age treated with three monthly doses of dihydroartemisinin-piperaquine (with two neighboring villages as controls), lower malaria incidence was observed among those who received treatment (53.4 percent, 95% CI 0.34-0.62) after six months [<a href="#rid73">73</a>].</p><p></p><p class="headingAnchor" id="H2587497582"><span class="h5">Infants with congenital HIV exposure</span><span class="headingEndMark"> — </span>To reduce the likelihood of opportunistic infection among infants exposed to HIV, the WHO recommends that these individuals begin <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (cotrimoxazole) between four and six weeks of age and continue until at least six weeks after cessation of breastfeeding and until HIV infection has been ruled out [<a href="#rid74">74</a>]. Prophylaxis with trimethoprim-sulfamethoxazole protects against malaria as well as Pneumocystis jirovecii infection. </p><p>This approach is supported by findings from an observational cohort study of HIV-exposed infants between 6 and 36 weeks of age in Malawi in which use of <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> preventive therapy was associated with a relative reduction in the risk of asymptomatic infection by 70 percent (95% CI 53-81 percent) [<a href="#rid75">75</a>]. Similar findings have been observed among older children; in a randomized trial among 541 children 1 to 14 years of age with HIV infection in Zambia randomly assigned to receive daily trimethoprim-sulfamethoxazole or placebo, the mortality rate after median follow-up of 19 months was lower among those who received cotrimoxazole (28 versus 42 percent; hazard ratio 0.57, 95% CI 0.43-0.77); a similar reduction in mortality was observed in a subgroup of children &lt;5 years (RR 0.68, 95% CI 0.51-0.91) [<a href="#rid76">76</a>]. </p><p class="headingAnchor" id="H1254858911"><span class="h4">Pregnant women</span><span class="headingEndMark"> — </span>Intermittent preventive treatment (IPT) is effective for reducing the risk of malaria infection among pregnant women (IPTp) [<a href="#rid11">11,77</a>]. This issue is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4812.html" rel="external">"Malaria in pregnancy: Prevention and treatment"</a>.)</p><p class="headingAnchor" id="H1889985688"><span class="h4">Patients with HIV infection</span><span class="headingEndMark"> — </span>We favor use of <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX; cotrimoxazole) for prevention of malaria in HIV-infected patients with any CD4 count living in malaria-affected areas. </p><p>Prophylaxis with TMP-SMX reduces morbidity and mortality rates due to malaria in HIV-infected individuals, even in areas with a high rate of malaria resistance [<a href="#rid78">78-82</a>]. </p><p class="headingAnchor" id="H17275836"><span class="h4">Patients with sickle cell disease</span><span class="headingEndMark"> — </span>Routine malaria prophylaxis is warranted for patients with sickle cell disease in areas where malaria is transmitted; this issue is discussed further separately. (See  <a class="medical medical_review" href="/d/html/99489.html" rel="external">"Sickle cell disease in sub-Saharan Africa"</a>.)</p><p class="headingAnchor" id="H4103434742"><span class="h3">Mass drug administration</span><span class="headingEndMark"> — </span>Issues related to chemoprevention for specific groups are discussed above. (See <a class="local">'Specific target groups'</a> above.) </p><p class="headingAnchor" id="H3757532662"><span class="h4">Antimalarial agents</span><span class="headingEndMark"> — </span>Mass drug administration (MDA) campaigns can rapidly reduce malaria parasitemia in low-transmission areas, and have been used in the setting of threatened <em>P. falciparum</em> drug resistance [<a href="#rid83">83</a>]. This was demonstrated by a randomized trial in Zambia in which patients received two doses of dihydroartemisinin-piperaquine or no treatment [<a href="#rid84">84</a>]. In low-transmission areas, an 87 percent reduction in parasite prevalence (from 7.71 to 0.54 percent) and 70 percent decrease in parasitemia was observed after five months.</p><p>However, in high-transmission areas, MDA may not be effective at reducing transmission. A systematic review of cluster-randomized controlled trials conducted in moderate to high transmission areas showed no overall impact of MDA on parasite prevalence (risk ratio 1.76; 95% confidence interval 0.58-5.36) one to three months after the MDA was over [<a href="#rid85">85</a>].</p><p>Regionally targeted MDA may be beneficial in some circumstances:</p><p class="bulletIndent1"><span class="glyph">●</span>A regional elimination program in Myanmar included identification of malarial "hotspots" (defined as presence of malaria in &gt;40 percent of individuals, of which 20 percent was <em>P. falciparum</em>); hotspot villages had incidence of <em>P. falciparum</em> three times higher than neighboring villages [<a href="#rid86">86</a>]. MDA (dihydroartemisinin-piperaquine plus single-dose <a class="drug drug_general" data-topicid="9810" href="/d/drug information/9810.html" rel="external">primaquine</a> once per month for three consecutive months) was targeted to individuals in these areas; the intervention was associated with an 80 percent reduction in incidence of <em>P. falciparum</em> (adjusted incidence rate ratio 0.19, 95% CI 0.13-0.26).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the Gambia (where there is seasonal falciparum malaria transmission), annual MDA with dihydroartemisinin-piperaquine in 2014-2015 in six village pairs prior to malaria season was associated with reduced infection and clinical disease during the first months. Reduction was maintained in low-transmission areas in eastern Gambia, but not in high-transmission areas [<a href="#rid87">87</a>]. </p><p></p><p>Another approach to targeted MDA consists of identifying asymptomatic individuals with malaria followed by "focal" MDA:</p><p class="bulletIndent1"><span class="glyph">●</span>In Zanzibar (an area of low falciparum transmission), drug treatment of all individuals residing within 300 to 1000 meters of individuals with positive rapid diagnostic tests enabled elimination of malaria in up to 66 percent of asymptomatic individuals [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a Cambodian trial of MDA (three monthly rounds of a three-day course of dihydroartemisinin-piperaquine) in four malaria-affected villages, the incidence of <em>P. falciparum</em> was lower in intervention villages than in the control villages during the subsequent 12 months (1.5 versus 37.1 cases per 1000 person years; incidence rate ratio 24) [<a href="#rid89">89</a>]. Artemisinin and incipient piperaquine resistance has emerged in the study area; the research team used artesunate-mefloquine for treatment failures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In Indonesia, a trial of malaria screening (with microscopy) and targeted treatment (with dihydroartemisinin-piperaquine) in a low transmission area did not impact the level of parasitemia level among school children [<a href="#rid90">90</a>]. The observed poor impact was ascribed to untreated microscopically subpatent infections in the control group. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study in Zambezi (Namibia) a setting with low levels of malaria transmission compared "reactive case detection" (finding and treating patients only) with treating persons in nearby areas around the malarious patients with focal MDA and reactive focal vector control. The incidence of malaria was lower among those who received focal MDA plus reactive focal vector control than among those receiving reactive case detection only (adjusted incidence rate ratio 0.26, 95% CI 0.10-0.68) [<a href="#rid91">91</a>].</p><p></p><p class="headingAnchor" id="H4172188773"><span class="h4">Systemic insecticides</span><span class="headingEndMark"> — </span>Mass administration of systemic insecticides (also known as endectocides) to reduce malaria transmission is an area of growing interest. </p><p><a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">Ivermectin</a> is promising systemic insecticide; it is capable of killing anopheline mosquitoes when they blood feed on ivermectin-treated individuals [<a href="#rid92">92</a>]. In a cluster-randomized trial including more than 2700 children in Burkina Faso (median age 15 years, including 590 children ≤5 years) treated with single oral doses of ivermectin (150 to 200 mcg/kg) and <a class="drug drug_general" data-topicid="9371" href="/d/drug information/9371.html" rel="external">albendazole</a> (400 mg), those in the intervention group received five additional doses of ivermectin at three-week intervals over the 18-week treatment phase [<a href="#rid93">93</a>]. The cumulative malaria incidence was lower in the intervention group than the control group (2.0 versus 2.49 episodes per child; risk difference -0.49, 95% CI -0.79 to -0.21); there was no difference in adverse events between the groups. </p><p>Membrane feeding of mosquitoes on patients' venous blood (rather than direct skin feeding) has been proposed as an alternative method for assessment of <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> mosquitocidal efficacy. In one study including comparing these approaches, mosquitocidal effects of ivermectin were similar across a range of drug concentrations [<a href="#rid94">94</a>].</p><p>Further study is needed to use of <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> in other areas, establish the optimal dose or formulation, and evaluate the effects of repeated ivermectin treatment.</p><p class="headingAnchor" id="H1024292930"><span class="h2">Vaccination</span><span class="headingEndMark"> — </span>A successful malaria vaccine has potential to reduce the global disease burden due to malaria [<a href="#rid95">95,96</a>]. Many antigens have been identified as potential targets for malaria vaccine development.</p><p>The WHO has approved two vaccines for prevention of malaria: the RTS,S/AS01 vaccine and the R21/Matrix-M vaccine for children living in areas of high transmission. It is difficult to compare vaccine efficacy between these vaccines based on available data due to differences in study settings and study design.</p><p class="headingAnchor" id="H3099426554"><span class="h3">RTS,S/ASO1 vaccine</span><span class="headingEndMark"> — </span>The WHO approved the RTS,S/AS01 vaccine in October 2021 for children in sub-Saharan Africa and other regions with moderate to high transmission, based on studies of 830,000 children in Ghana, Kenya, and Malawi [<a href="#rid3">3,97</a>].</p><p>The RTS,S/AS01 vaccine consists of a recombinant fusion protein created based on an antigen target consisting of a repetitive sequence of four amino acids in the circumsporozoite antigen on the surface of the <em>P. falciparum</em> sporozoite  (<a class="graphic graphic_figure graphicRef70176" href="/d/graphic/70176.html" rel="external">figure 3</a>) [<a href="#rid98">98-103</a>]. "RTS" stands for "repeat T epitopes" derived from the circumsporozoite protein, "S" stands for the S antigen derived from hepatitis B surface antigen (HBSAg), and AS01 is a proprietary adjuvant [<a href="#rid104">104</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>Phase 3 trial results of the RTS,S/AS01 vaccine among 15,459 infants demonstrated that the vaccine induced partial protection against clinical malaria among children ages 5 to 17 months over the follow-up period of the trial (median 48 months) and demonstrated benefit of the 20-month booster [<a href="#rid103">103</a>]. In the intention-to-treat population, vaccine efficacy among children ages 5 to 17 months who received three doses plus a booster (months 0, 1, 2, and 20) was 36 percent (95% CI 32-40). This finding is a decline from the 50 percent efficacy (95% CI 46-55) reported over the 14 months from the first dose [<a href="#rid99">99</a>]. No significant efficacy against severe malaria was noted in the 6 to 12 week age group over the duration of the trial, even with a booster.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another RTS,S/AS01 vaccine trial including 447 children ages 5 to 17 months who received three doses of RTS,S/AS01 vaccine noted a decline of vaccine efficacy against malaria between the first and fourth years of follow-up, from 44 percent (95% CI 16-62) to zero [<a href="#rid101">101</a>]. Subsequent follow-up of the vaccine recipients in the intention-to-treat cohort at seven years was notable for overall efficacy of 4.4 percent; efficacy was 16.6 percent in the low-exposure group but was negative (-2.4 percent) in the high-exposure group [<a href="#rid105">105</a>]. Additional follow-up for those who received a four-dose vaccine regimen is pending.</p><p></p><p>The RTS,S/AS01 vaccine has been observed to afford greater protection against clinical malaria infection caused by parasites that match the vaccine in the circumsporozoite protein allele than malaria infection caused by parasites with a mismatched allele [<a href="#rid106">106</a>].</p><p class="headingAnchor" id="H862552461"><span class="h3">R21/Matrix-M vaccine</span><span class="headingEndMark"> — </span>The WHO approved the R21/Matrix-M vaccine in October 2023 for prevention of malaria in children living in areas of moderate to high transmission [<a href="#rid107">107</a>]. The R21 vaccine is a virus-like protein based on the circumsporozoite protein from <em>P. falciparum </em>strain NF54, fused to the N-terminus of HBsAg; it is manufactured using Matrix-M, a proprietary adjuvant. </p><p class="bulletIndent1"><span class="glyph">●</span>In a phase 3 trial in Burkina Faso, Kenya, Mali, and Tanzania, 4800 children (age 5 to 36 months) were randomly assigned to receive a three-dose vaccine series or placebo [<a href="#rid108">108</a>]. At 12 months, vaccine efficacy against clinical malaria was 75 percent (95% CI 71-79) at the sites with seasonal malaria transmission and 68 percent (95% CI 61-74) at the sites with year-round malaria transmission. The vaccine was well tolerated; injection site pain and fever were most frequent adverse events. These data are under peer review prior to publication. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a phase 2 trial including 450 children (age 5 to 17 months) in Burkina Faso (a highly seasonal transmission setting) randomly assigned to receive three doses of R21/MM vaccine (with low- or high-dose adjuvant MM) or <a class="drug drug_general" data-topicid="9850" href="/d/drug information/9850.html" rel="external">rabies vaccine</a>, vaccine efficacy in the two treatment groups more than 6 months after vaccination was 74 percent (95% CI 63-82 percent) and 77 percent (95% CI 67-84 percent), respectively [<a href="#rid109">109</a>]. There were no serious adverse events related to vaccination. The trial was performed in the context of substantial ITN use, moderate seasonal malaria prophylaxis, and minimal indoor residual spraying. </p><p></p><p class="bulletIndent1">Data on the durability of protection are particularly important for malaria vaccines, since, depending on the regional transmission intensity, the risk of death due to malaria may continue for many years. </p><p></p><p class="headingAnchor" id="H2920510046"><span class="h2">Monoclonal antibodies</span><span class="headingEndMark"> — </span>Use of monoclonal antibodies represents a novel approach to providing immune protection for malaria prevention. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>L9LS</strong> – A phase 1 clinical trial evaluated L9LS, a monoclonal antibody against <em>P. falciparum</em> infection that targets the circumsporozoite protein on the parasite surface during the sporozoite stage (when infection is transmitted to establish infection in the liver); this is also the target of the RTS,S/ASO1 and R21-Matrix vaccines [<a href="#rid110">110</a>].</p><p></p><p class="bulletIndent1">The trial enrolled healthy adults in the United States with no history of malaria infection or vaccination; 18 individuals received L9LS (serum half-life 56 days) and a control group of 9 individuals did not receive L9LS. Both groups underwent controlled malaria infection; protection against infection was greater among those who received L9LS than those who did not (88 versus 0 percent). No serious adverse events were reported. A subcutaneously delivered preparation also demonstrated good protection, and phase 2 studies are underway.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CIS43LS</strong> – A phase 2 clinical trial evaluated CIS43LS, a different monoclonal antibody against the <em>Plasmodium falciparum</em> sporozoite circumsporozoite protein [<a href="#rid111">111</a>].</p><p></p><p class="bulletIndent1">The trial included more than 200 healthy adults in Mali who were randomly assigned to receive an infusion of CIS43LS dosed at 10 mg/kg, 40 mg/kg, or placebo. In addition, <a class="drug drug_general" data-topicid="9066" href="/d/drug information/9066.html" rel="external">artemether-lumefantrine</a> was administered prior to infusion to clear subclinical infection if present. The efficacy for the primary endpoint (first <em>P. falciparum</em> infection detected on blood smear examination performed at least every 2 weeks for 24 weeks) among those who received high-dose CIS43LS was 88 percent (adjusted 95% CI 79-93). Moderate headache occurred 3.3 times more frequently among those who received high-dose CIS43LS compared with placebo.</p><p></p><p class="bulletIndent1">Study limitations include lack of information on the incidence of clinical malaria (since this was not a secondary endpoint) and limitation of study enrollment to healthy nonpregnant adults (whose lifelong malaria exposure confers substantial immunity). In addition, intravenous infusion is impractical; development of a more robust formulation would be needed for subcutaneous administration.</p><p></p><p>This tool for malaria prevention may be useful for individuals who are unable to mount an immune response to vaccination, as well as for individuals in regions with emerging antimalarial resistance and in settings of malaria outbreaks. Larger studies in malaria-affected settings and among children and pregnant patients is needed. </p><p class="headingAnchor" id="H6"><span class="h1">MOSQUITO CONTROL</span><span class="headingEndMark"> — </span>Important mosquito vectors in malarious areas are summarized in the table  (<a class="graphic graphic_table graphicRef56132" href="/d/graphic/56132.html" rel="external">table 1</a>).</p><p>Mosquito vector control methods that can be deployed over large areas include use of insecticide-treated nets (ITNs) and household insecticide indoor residual spraying (IRS). Larval source management, which includes application of larvicides, is considered a supplemental vector control methods that may complement ITNs and IRS in areas where larval habitats are few, fixed and findable. Genetic control methods remain an area of research. Since effective insecticides have become available for use against adult <em>Anopheles</em>, ITNs and IRS have become the most important measures for mosquito vector control.</p><p>Requirements for effective sustained implementation of vector control include [<a href="#rid112">112</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Continual monitoring for <em>Anopheles</em> resistance and cross-resistance to the insecticides deployed</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Entomology expertise (including mosquito species identification and their biting and feeding habits) and vector control technology</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Close supervision and monitoring of the effect of the intervention on the entomological inoculation rates and on clinical and parasitologic indices</p><p></p><p>The behavior of the vector is important for determining the choice of control method [<a href="#rid113">113</a>]. For mosquitoes that prefer to rest indoors (endophilic) and feed indoors (endophagic) at night, both IRS and ITNs are effective methods of control. For mosquitoes that prefer to rest outdoors (exophilic) and feed outdoors (exophagic) earlier in the day (eg, the South American vector <em>Anopheles albimanus</em>), the use of repellents may be the only feasible method of control. If the vector has clearly defined breeding sites (for example, <em>Anopheles stephensi</em>), then larval control measures can be applied [<a href="#rid113">113</a>]. However, an integrated control strategy is often the most successful approach [<a href="#rid114">114</a>].</p><p>Studies carried out prior to the implementation of a mosquito control program should survey the local mosquito population, identify vector species, and identify the most anthropophilic species [<a href="#rid115">115</a>]. The type and degree of insecticide resistance present in the mosquito population should also be investigated [<a href="#rid116">116,117</a>].</p><p>Mosquitoes progress through four distinct life stages: egg, larva, pupa, and adult [<a href="#rid118">118</a>]. The full life cycle usually takes approximately 10 days and varies according to species, season, temperature, and available nutrition.</p><p class="headingAnchor" id="H851845465"><span class="h2">Mosquito life cycle</span><span class="headingEndMark"> — </span>Stages of the mosquito life cycle include egg, larva, pupa and adult.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eggs</strong> – Female mosquitoes lay up to 200 cigar-shaped eggs per reproductive cycle  (<a class="graphic graphic_figure graphicRef53881" href="/d/graphic/53881.html" rel="external">figure 4</a>). <em>Anopheles</em> eggs have "floats" (sacs on the side of the egg). <em>Anopheles</em> and <em>Aedes</em> mosquitoes lay eggs individually; <em>Culex</em> mosquito lay eggs in groups ("egg rafts").</p><p></p><p class="bulletIndent1"><em>Anopheles</em> mosquitoes lay eggs in clean water (such as rain puddles, water tanks, and irrigation ditches). <em>Aedes</em> mosquitoes (sometimes called "floodwater mosquitoes") lay eggs in moist environments with potential to be submerged; the eggs can withstand desiccation until a flooding event occurs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Larva </strong>– Eggs hatch into larvae that live in the water and come to the surface to breathe  (<a class="graphic graphic_figure graphicRef53881" href="/d/graphic/53881.html" rel="external">figure 4</a>). <em>Anopheles</em> larvae lie in a horizontal position parallel to the water surface and do not have a siphon. <em>Culex</em> larvae maintain a position vertical to the water surface and breathe via a siphon, which extends to the water surface.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pupa</strong> – Pupae float on the water surface  (<a class="graphic graphic_figure graphicRef53881" href="/d/graphic/53881.html" rel="external">figure 4</a>). In the pupa stage, the head and thorax are fused to form a comma-shaped cephalothorax; during this stage, there are no distinguishing characteristics between the genera. Pupae breathe but do not feed, so larvicide cannot be ingested during this stage, although surface oil can induce suffocation. Metamorphosis from pupa into an adult mosquito takes about two days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adult </strong>– The newly emerged adult female is able to mate immediately; the male mosquito is able to mate 24 hours after emergence. Only female mosquitoes bite humans or animals to obtain protein needed for producing eggs; both males and females feed on flower nectar for food. Female mosquitoes begin blood feeding approximately three days post-emergence.</p><p></p><p class="bulletIndent1">Mosquito head appendages consist of a proboscis, a pair of antennae, and a pair of maxillary palps  (<a class="graphic graphic_figure graphicRef82494" href="/d/graphic/82494.html" rel="external">figure 5</a>). Female mosquitoes use the proboscis to pierce skin and suck blood. Male antennae are bushier than female antennae and are visible with the naked eye. The palp characteristics are the most reliable for differentiation between anopheline and culicine mosquitoes. Anopheline female palps are about the same length as the proboscis, while Anopheline male palps are club shaped at the ends. Culicine female palps are shorter than the proboscis, and Culicine male palps are long with a tapered point.</p><p></p><p class="bulletIndent1">Live adult mosquitoes are recognizable by their stance at rest. Anopheline mosquitoes are oriented with head, thorax, and abdomen in a straight line at an acute angle to the surface, while Culicine mosquitoes rest with the head and body angled and the abdomen directed back to the surface  (<a class="graphic graphic_figure graphicRef71887" href="/d/graphic/71887.html" rel="external">figure 6</a>).</p><p></p><p class="headingAnchor" id="H823011174"><span class="h2">Residential interventions</span><span class="headingEndMark"> — </span>Residential interventions include house screening, indoor residual spraying, and lethal house lures. The WHO recommends house screening [<a href="#rid46">46</a>], although there are no good data evaluating the effectiveness of this intervention. Data evaluating indoor residual spraying and lethal house lures are discussed below. </p><p class="headingAnchor" id="H8"><span class="h3">Indoor residual spraying</span><span class="headingEndMark"> — </span>Indoor residual spraying (IRS) involves spraying insecticide on indoor residential walls and ceilings; depending on the insecticide and surface, the effect can last for extended periods. The WHO recommends that effort be focused on optimal implementation of either ITNs or IRS, rather than deploying both in the same area. In settings where ITNs remain effective and optimal ITN coverage has been achieved, additional implementing of IRS may have limited utility [<a href="#rid46">46</a>]. (See <a class="local">'Insecticide-treated nets (ITNs)'</a> above.)</p><p>IRS is performed with hand-operated compression sprayers containing an aqueous suspension of insecticide. Spray teams must be trained and supervised closely in applying the correct dose to walls and ceilings and protecting themselves from toxicity [<a href="#rid119">119</a>]. Frequency of IRS application varies from once or twice yearly for organochlorine compounds (eg, DDT) to three or more times for organophosphates (eg, <a class="drug drug_general" data-topicid="9584" href="/d/drug information/9584.html" rel="external">malathion</a>) [<a href="#rid120">120</a>].</p><p>Mosquito contact with insecticide-treated surfaces is generally lethal; sublethal exposure drives mosquitoes outside the house. Ideally, the mosquito is killed or repelled before feeding on humans within the dwelling [<a href="#rid121">121</a>]. Widespread community IRS reduces the proportion of mosquitoes surviving long enough to transmit malaria since each mosquito attempt at a blood meal results in a potentially lethal insecticide exposure [<a href="#rid113">113,120,122</a>]. Community health education about IRS is essential; spraying may require furniture rearrangements, the walls may become streaked with chemical treatments, and there may be a residual odor from the IRS.</p><p>DDT was once a widely used IRS insecticide based on its efficacy, low cost, low toxicity, and length of effect. DDT was used for IRS programs that achieved malaria elimination in many areas in the 1940s and 1950s (including the southern United States, most Caribbean islands, southern Europe, most of the former USSR, and Taiwan). It has also been used successfully for reducing malaria prevalence in south Asia, southern Africa, South America, and Zanzibar [<a href="#rid22">22,123,124</a>].</p><p>In the mid-1990s, many regions switched from DDT to pyrethroids for IRS. This resulted from environmental concerns about toxicity and pressure against DDT use, and there has been a reduction in production of the compound. Given the environmental concerns and the lack of a WHO prequalified DDT product, DDT is now rarely used in IRS programs.</p><p>The combined effect of IRS and ITNs is uncertain. One study in Uganda noted that the combination of IRS and ITNs was associated with a marked decline in the burden of malaria; use of ITNs alone had a modest impact [<a href="#rid125">125</a>]. However, a study in Uganda (where high-level coverage of ITNs was achieved) showed that stopping IRS after four years of twice-yearly household spraying was associated with a rapid increase in malaria morbidity to pre-IRS levels [<a href="#rid126">126</a>]. Mosquito resistance to pyrethroids used in the ITNs is one of the possible reasons for resurgence of malaria; in one review, of communities using ITNs, the addition of IRS with 'non-pyrethroid-like' insecticides was associated with reduced malaria prevalence [<a href="#rid61">61</a>].</p><p>In some cases, use of IRS, even with ITNs and selective drug use, is not effective for elimination of transmission. In one study including more than 400 individuals in northern Uganda from 2014 to 2016, three rounds of IRS with carbamate bendiocarb reduced the incidence of clinical malaria and the prevalence of parasitemia; however, the parasitemia prevalence remained at 11.3 percent among children &lt;5 years of age and at &gt;15 percent in older age groups [<a href="#rid127">127</a>]. A subsequent study among more than 300 children between 6 months and 10 years of age in Uganda observed that multiple rounds of IRS (three rounds of carbamate bendiocarb followed by one round of an organophosphate, Actellic CS) was associated with decreased incidence of clinical malaria (by 83 percent) and increased hemoglobin level (by 10 percent) [<a href="#rid128">128</a>]. </p><p>In areas with relatively low transmission and a strong surveillance program, targeted IRS (use of IRS only at the houses of individuals with malaria and their neighbors) may be more cost-effective than mass IRS. In a cluster-randomized study in South Africa, the incidence of malaria among clusters managed with mass IRS was similar to the incidence among clusters managed with targeted IRS (0.95 cases versus 1.05 cases per 1000 person-years) [<a href="#rid129">129</a>]. At this disease incidence, use of targeted IRS would have a 94 to 98 percent probability of being cost-effective, up to an incidence of 2.0 to 2.7 cases per 1000 person-years. The generalizability of the findings in higher transmission settings warrants further study. </p><p class="headingAnchor" id="H4134880836"><span class="h3">Lethal house lures</span><span class="headingEndMark"> — </span>A lethal house lure is a novel intervention for mosquito control. One approach consists of window screening in combination with installation of ventilation tubes in house eaves; the tubes funnel heat and odor cues (which attract mosquitoes) and contain powdered insecticide. In a cluster-randomized trial in Côte d’Ivoire including more than 8000 houses and 2000 children, a lower incidence of malaria was observed among the intervention group (use of a lethal house lure in addition to ITNs) than the control group (use of ITNs alone; 1.43 versus 2.29 per child-year; hazard ratio 0.62, 95% CI 0.51-0.76) [<a href="#rid130">130</a>]. No serious adverse events associated with the intervention were reported during follow-up. Further study is needed for additional optimization. </p><p class="headingAnchor" id="H711313033"><span class="h2">Vector control strategies</span><span class="headingEndMark"> — </span>Tools for vector control include larval control and genetic control.</p><p class="headingAnchor" id="H9"><span class="h3">Larval source management</span><span class="headingEndMark"> — </span>Larval source management (LSM) includes modification and manipulation of larval sites, larviciding and biological control (eg. Larvivorous fish). For regions with ongoing malaria transmission, WHO recommends that larviciding may be used as a supplementary intervention for malaria control in settings where aquatic habitats are few, fixed, and findable [<a href="#rid46">46</a>]. Larviciding should not be considered a substitute for ITNs or IRS; larviciding reduces vector density, which does not have the same potential impact as ITNs and IRS (which reduce vector longevity and provide protection from biting vectors). </p><p>Evidence for other LSM activities are limited and highly context specific. However, several temperate countries, for example, the US and Italy, achieved significant reductions in malaria through large-scale environmental manipulation of aquatic habitats.</p><p>LSM is one of the strategies recommended by WHO to contain the spread of <em>An. stephensi</em> in urban and peri-urban areas [<a href="#rid131">131</a>]. LSM includes, where feasible, removal of larval sites, modification of larval sites to prevent mosquito access and larviciding with WHO-prequalified chemical or biological larvicides.</p><p>Prior to availability of insecticides for use against adult mosquitoes, a concerted effort was directed toward making potential breeding sites unsuitable for <em>Anopheles</em> larvae. Famous historical examples include fluctuation of water levels in the reservoirs of the Tennessee Valley Authority and the draining of the Pontine Marshes near Rome [<a href="#rid114">114</a>].</p><p>Larval control is challenging in that virtually all potential breeding places within mosquito flight range of the human community must be identified and addressed. To prevent anopheline population explosions, drainage and filling of water collection sites as well as careful management of large engineering projects such as dam and building construction are needed.</p><p>Larvivorous fish species (eg, <em>Gambusia</em> and <em>Poecilia</em>) are avid feeders on mosquito larvae and may be used to stock village wells and ponds (the breeding places of local mosquito vectors) [<a href="#rid132">132</a>]. This strategy was implemented in a series of villages in south India; from 1998 (over one year after release of fish) until 2003, no malaria cases were detected in the villages [<a href="#rid114">114,133</a>]. This method also allows villagers to continue their traditions of raising indoor silkworm moths without the threat of insecticide damage.</p><p>Insect growth regulators such as pyriproxyfen (in a sand granule formulation) may be used in water-filled pits to prevent metamorphosis from larva to pupa to adult. This technique was used in Sri Lanka, where malaria eradication was nearly achieved in the 1960s but disease persisted in areas where pits were dug in search of gems (subsequently, the pits filled with rainwater and became breeding sites for malaria vectors) [<a href="#rid134">134</a>]. Treatment of all the pits in four villages achieved reduction in incidence of malaria cases (compared with untreated villages). Retreatment two to three times a year was sufficient.</p><p>Use of larval control techniques in Africa has been nearly impossible since breeding sites of <em>An. gambiae</em> tend to be small and impermanent. However, a major reduction in the density of adult <em>An. gambiae</em> was achieved in a Kenyan village by use of the bacterial toxin <em>Bacillus thuringiensis</em> israelensis (Bti). This toxin is highly specific for mosquito larvae and targets very few other species [<a href="#rid135">135</a>]. Bti has a short half-life, and over 400 potential breeding sites were checked weekly and retreated, if necessary. <em>An. funestus</em> may be a more feasible target for antilarval control measures in Africa given that its breeding sites are larger and more permanent.</p><p>A problem with many of the biological control approaches to larval control has been that they are difficult to expand to large scale or national public usefulness. This is because of the site-specific nature of the research and other constraints. In some projects, the imported fish species did not adapt to local conditions and they were avidly consumed by the human populations they were to protect.</p><p class="headingAnchor" id="H10"><span class="h3">Genetic control</span><span class="headingEndMark"> — </span>Genetic strategies for malaria control entail using male mosquitoes to introduce genetic factors that prevent the eggs from hatching, prevent the larvae from surviving, or produce adult insects incapable of transmitting human disease. Despite years of investigation, genetic control remains a promising research theme.</p><p>To prevent eggs from hatching or larvae from surviving, males carrying sterilizing factors (dominant lethal mutations introduced by irradiation of the adult male) compete for mates in a target population of females who have not already mated with fertile males [<a href="#rid136">136</a>]. This is known as the sterile insect technique (SIT). Experience with SIT for <em>Anopheles</em> mosquitoes is limited, although the technique has been successful for eradication of other pests [<a href="#rid137">137</a>].</p><p>To produce adult insects incapable of transmitting disease, a transgenic system has been developed that greatly reduces susceptibility of <em>An. stephensi</em> to infection with rodent malaria [<a href="#rid138">138</a>]. It is hoped that similar approaches will soon produce strains completely non-susceptible to <em>P. falciparum</em> [<a href="#rid138">138,139</a>]. However, the optimal approach for creating genetic factors that selectively incorporate themselves into later generations in a wild population is under intense study but remains uncertain [<a href="#rid140">140-142</a>].</p><p class="headingAnchor" id="H1141001085"><span class="h1">PROGRESS TO ELIMINATION</span><span class="headingEndMark"> — </span>In 2014, 16 countries reported zero indigenous cases (Argentina, Armenia, Azerbaijan, Costa Rica, Iraq, Georgia, Kyrgyzstan, Morocco, Oman, Paraguay, Sri Lanka, Tajikistan, Turkey, Turkmenistan, the United Arab Emirates, and Uzbekistan). Another three countries and territories reported fewer than 10 indigenous cases (Algeria, El Salvador, and Mayotte [France]). The WHO European Region reported zero indigenous cases for the first time in 2015, and Sri Lanka was declared free of malaria in 2016 [<a href="#rid143">143</a>]. </p><p>Globally, the elimination net is widening; in 2021, 46 countries reported fewer than 10,000 cases (up from 40 countries in 2010). The number of countries with less than 100 indigenous cases increased from 17 to 27 countries between 2010 and 2017 [<a href="#rid143">143</a>]. A total of 15 countries have been certified malaria-free since 2000, including Azerbaijan, Belize, China, El Salvador and Tajikistan [<a href="#rid6">6</a>].  </p><p>Stringent environmental management and "integrated vector control" (concurrent use of multiple approaches) are required for eradication. Long-lasting insecticidal nets and indoor residual spraying are strategic components for all three groups; these and other strategies are discussed above. (See <a class="local">'Elements for malaria control and elimination'</a> above.)</p><p class="headingAnchor" id="H2781288902"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113035.html" rel="external">"Society guideline links: Malaria"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Malaria is the most important parasitic disease of humans, with transmission in 84 countries affecting over 3 billion people and likely causing over 600,000 deaths each year. Important challenges to malaria elimination include parasite drug resistance, mosquito insecticide resistance, geographic expansion of mosquito species from other regions and the spread of parasites that do not express the proteins detected by rapid diagnostic tests. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To consider interventions for malaria control, it is important to define goals of control, elimination, and eradication. Control is reduction of disease incidence and prevalence to levels that do not pose a threat to public health or that are acceptable to a community. Elimination is reduction to zero transmission in humans in a defined geographic area. Eradication is global elimination of human disease. (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chemoprevention appears to be useful for reducing the consequences of malaria infection among individuals at high risk, particularly pregnant women. IPTp, and seasonal and perennial chemoprevention of high risk groups are important recommendations in WHO’s malaria guidelines. (See <a class="local">'Specific target groups'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mosquito vector control methods include use of ITNs, household insecticide residual spraying (IRS), larval control, and genetic control methods. Since effective insecticides for use against adult <em>Anopheles</em> have become available, ITNs and IRS have become the most important measures for mosquito vector control. (See <a class="local">'Mosquito control'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The efficacy of mosquito repellents for protection against malaria is variable depending on the transmitting mosquito vector. (See <a class="local">'Repellents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mass drug administration may be a useful tool in regions where elimination of falciparum malaria is a feasible goal. An effective drug, rapid diagnostics, and sensitive monitoring system for adverse events are required for such an intervention. (See <a class="local">'Mass drug administration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malaria vaccines used in conjunction with other control interventions could reduce the global disease burden of malaria. (See <a class="local">'Vaccination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Measuring progress by continuous, timely, widely shared surveillance information is the key to control and eradication. Surveillance of the quality of antimalarial drugs (and other commodities) is essential to assure effective treatment and prevention. (See <a class="local">'Surveillance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Continuing research on the issues noted above is required to achieve control, elimination, and eradication of malaria in the 21<sup>st</sup> century. (See <a class="local">'Elements for malaria control and elimination'</a> above.)</p><p></p><p class="headingAnchor" id="H1840730818"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Joel G Breman, MD, DTPH, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">World Health Organization. WHO Guidelines for malaria 2022, 15 November 2022. https://www.who.int/publications/i/item/guidelines-for-malaria (Accessed on April 01, 2022).</li><li class="breakAll">World Health Organization. World malaria report 2022. https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2022 (Accessed on November 06, 2023).</li><li class="breakAll">World Health Organization. World malaria report 2021. https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2021 (Accessed on February 07, 2022).</li><li class="breakAll">World Health Organization. Strategy to respond to antimalarial drug resistance in Africa. https://www.who.int/publications/i/item/9789240060265 (Accessed on November 06, 2023).</li><li class="breakAll">Mwaniki M, Prabhu M. Hope spreads as 18 million doses of the first malaria vaccine are allocated to 12 African countries. Gavi, the Vaccine Alliance. https://www.gavi.org/vaccineswork/hope-spreads-18-million-doses-first-malaria-vaccine-are-allocated#:~:text=These%2018%20million%20first%20doses,for%20the%20period%202023%2D2025. (Accessed on November 06, 2023).</li><li class="breakAll">World Health Organization. Countries and territories certified malaria-free by WHO. Global Malaria Programme. https://www.who.int/teams/global-malaria-programme/elimination/countries-and-territories-certified-malaria-free-by-who (Accessed on November 06, 2023).</li><li><a class="nounderline abstract_t">Owusu-Ofori AK, Betson M, Parry CM, et al. Transfusion-transmitted malaria in Ghana. Clin Infect Dis 2013; 56:1735.</a></li><li><a class="nounderline abstract_t">Gruell H, Hamacher L, Jennissen V, et al. On Taking a Different Route: An Unlikely Case of Malaria by Nosocomial Transmission. Clin Infect Dis 2017; 65:1404.</a></li><li><a class="nounderline abstract_t">Mace KE, Lucchi NW, Tan KR. Malaria Surveillance - United States, 2017. MMWR Surveill Summ 2021; 70:1.</a></li><li><a class="nounderline abstract_t">Smith T, Maire N, Dietz K, et al. Relationship between the entomologic inoculation rate and the force of infection for Plasmodium falciparum malaria. Am J Trop Med Hyg 2006; 75:11.</a></li><li class="breakAll">WHO Global Malaria Control and Elimination: report of a technical review 17-18 January 2008. Geneva, pp. 1-47.</li><li class="breakAll">Bruce Chwatt LJ. Essential Malariology, Wiley Medical, 1985. p.193.</li><li class="breakAll">World Health Organization. Malaria surveillance, monitoring &amp; evaluation: a reference manual. https://www.who.int/publications/i/item/9789241565578 (Accessed on November 06, 2023).</li><li><a class="nounderline abstract_t">Kiszewski AE, Teklehaimanot A. A review of the clinical and epidemiologic burdens of epidemic malaria. Am J Trop Med Hyg 2004; 71:128.</a></li><li><a class="nounderline abstract_t">Mace KE, Lucchi NW, Tan KR. Malaria Surveillance - United States, 2018. MMWR Surveill Summ 2022; 71:1.</a></li><li><a class="nounderline abstract_t">Blackburn D, Drennon M, Broussard K, et al. Outbreak of Locally Acquired Mosquito-Transmitted (Autochthonous) Malaria - Florida and Texas, May-July 2023. MMWR Morb Mortal Wkly Rep 2023; 72:973.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Important Updates on Locally Acquired Malaria Cases Identified in Florida, Texas, and Maryland. https://emergency.cdc.gov/han/2023/han00496.asp#:~:text=On%20August%2018%2C%202023%2C%20a,transmission%20of%20Plasmodium%20vivax%20(P. (Accessed on November 06, 2023).</li><li class="breakAll">Centers for Disease Control and Prevention. Locally Acquired Cases of Malaria in Florida, Texas, Maryland, and Arkansas. https://www.cdc.gov/malaria/new_info/2023/malaria_US.html#:~:text=CDC%20is%20currently%20collaborating%20with,cases%20of%20malaria%20were%20reported (Accessed on January 16, 2024).</li><li><a class="nounderline abstract_t">Guerra CA, Gikandi PW, Tatem AJ, et al. The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Med 2008; 5:e38.</a></li><li><a class="nounderline abstract_t">Snow RW, Guerra CA, Noor AM, et al. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005; 434:214.</a></li><li><a class="nounderline abstract_t">Price RN, Tjitra E, Guerra CA, et al. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 2007; 77:79.</a></li><li><a class="nounderline abstract_t">Breman JG. Eradicating malaria. Sci Prog 2009; 92:1.</a></li><li><a class="nounderline abstract_t">White NJ. Plasmodium knowlesi: the fifth human malaria parasite. Clin Infect Dis 2008; 46:172.</a></li><li><a class="nounderline abstract_t">Fornace KM, Topazian HM, Routledge I, et al. No evidence of sustained nonzoonotic Plasmodium knowlesi transmission in Malaysia from modelling malaria case data. Nat Commun 2023; 14:2945.</a></li><li><a class="nounderline abstract_t">de Oliveira TC, Rodrigues PT, Early AM, et al. Plasmodium simium: Population Genomics Reveals the Origin of a Reverse Zoonosis. J Infect Dis 2021; 224:1950.</a></li><li class="breakAll">World Health Organization. A framework for malaria elimination. https://www.who.int/publications/i/item/9789241511988 (Accessed on November 06, 2023).</li><li><a class="nounderline abstract_t">Breman JG, Holloway CN. Malaria surveillance counts. Am J Trop Med Hyg 2007; 77:36.</a></li><li><a class="nounderline abstract_t">malERA Consultative Group on Health Systems and Operational Research. A research agenda for malaria eradication: health systems and operational research. PLoS Med 2011; 8:e1000397.</a></li><li><a class="nounderline abstract_t">Noor AM, Kinyoki DK, Mundia CW, et al. The changing risk of Plasmodium falciparum malaria infection in Africa: 2000-10: a spatial and temporal analysis of transmission intensity. Lancet 2014; 383:1739.</a></li><li><a class="nounderline abstract_t">Greenwood B, Koram K. Malaria control in Africa: progress but still much to do. Lancet 2014; 383:1703.</a></li><li><a class="nounderline abstract_t">Bhatt S, Weiss DJ, Cameron E, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature 2015; 526:207.</a></li><li><a class="nounderline abstract_t">Gething PW, Casey DC, Weiss DJ, et al. Mapping Plasmodium falciparum Mortality in Africa between 1990 and 2015. N Engl J Med 2016; 375:2435.</a></li><li><a class="nounderline abstract_t">Nayyar GM, Breman JG, Newton PN, Herrington J. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis 2012; 12:488.</a></li><li><a class="nounderline abstract_t">Nayyar GML, Breman JG, Mackey TK, et al. Falsified and Substandard Drugs: Stopping the Pandemic. Am J Trop Med Hyg 2019; 100:1058.</a></li><li><a class="nounderline abstract_t">Skarbinski J, Ouma PO, Causer LM, et al. Effect of malaria rapid diagnostic tests on the management of uncomplicated malaria with artemether-lumefantrine in Kenya: a cluster randomized trial. Am J Trop Med Hyg 2009; 80:919.</a></li><li><a class="nounderline abstract_t">Breman JG. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am J Trop Med Hyg 2001; 64:1.</a></li><li><a class="nounderline abstract_t">Alonso PL, Brown G, Arevalo-Herrera M, et al. A research agenda to underpin malaria eradication. PLoS Med 2011; 8:e1000406.</a></li><li><a class="nounderline abstract_t">Rabinovich RN, Drakeley C, Djimde AA, et al. malERA: An updated research agenda for malaria elimination and eradication. PLoS Med 2017; 14:e1002456.</a></li><li class="breakAll">World Health Organization. Global technical strategy for malaria 2016-2030, 2021 update. https://www.who.int/publications/i/item/9789240031357 (Accessed on November 06, 2023).</li><li class="breakAll">World Health Organization. High burden to high impact: a targeted malaria response. https://www.who.int/publications/i/item/WHO-CDS-GMP-2018.25 (Accessed on November 06, 2023).</li><li><a class="nounderline abstract_t">Chandramohan D, Zongo I, Sagara I, et al. Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention. N Engl J Med 2021; 385:1005.</a></li><li class="breakAll">Debboun M, Frances SP, Strickman D. Insect Repellents, CRC Press, Boca Raton 2007.</li><li><a class="nounderline abstract_t">Hill N, Lenglet A, Arnéz AM, Carneiro I. Plant based insect repellent and insecticide treated bed nets to protect against malaria in areas of early evening biting vectors: double blind randomised placebo controlled clinical trial in the Bolivian Amazon. BMJ 2007; 335:1023.</a></li><li><a class="nounderline abstract_t">Rowland M, Downey G, Rab A, et al. DEET mosquito repellent provides personal protection against malaria: a household randomized trial in an Afghan refugee camp in Pakistan. Trop Med Int Health 2004; 9:335.</a></li><li><a class="nounderline abstract_t">Pryce J, Richardson M, Lengeler C. Insecticide-treated nets for preventing malaria. Cochrane Database Syst Rev 2018; 11:CD000363.</a></li><li class="breakAll">WHO Guidelines for malaria, 14 March 2023. Geneva: World Health Organization; 2023. https://www.who.int/publications/i/item/guidelines-for-malaria (Accessed on April 03, 2023).</li><li><a class="nounderline abstract_t">Trape JF, Tall A, Diagne N, et al. Malaria morbidity and pyrethroid resistance after the introduction of insecticide-treated bednets and artemisinin-based combination therapies: a longitudinal study. Lancet Infect Dis 2011; 11:925.</a></li><li><a class="nounderline abstract_t">Asidi A, N'Guessan R, Akogbeto M, et al. Loss of household protection from use of insecticide-treated nets against pyrethroid-resistant mosquitoes, benin. Emerg Infect Dis 2012; 18:1101.</a></li><li><a class="nounderline abstract_t">Curtis CF, Maxwell CA, Finch RJ, Njunwa KJ. A comparison of use of a pyrethroid either for house spraying or for bednet treatment against malaria vectors. Trop Med Int Health 1998; 3:619.</a></li><li><a class="nounderline abstract_t">Hemingway J, Ranson H, Magill A, et al. Averting a malaria disaster: will insecticide resistance derail malaria control? Lancet 2016; 387:1785.</a></li><li><a class="nounderline abstract_t">Henry MC, Assi SB, Rogier C, et al. Protective efficacy of lambda-cyhalothrin treated nets in Anopheles gambiae pyrethroid resistance areas of Côte d'Ivoire. Am J Trop Med Hyg 2005; 73:859.</a></li><li><a class="nounderline abstract_t">Gleave K, Lissenden N, Richardson M, et al. Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa. Cochrane Database Syst Rev 2018; 11:CD012776.</a></li><li><a class="nounderline abstract_t">Gleave K, Lissenden N, Chaplin M, et al. Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa. Cochrane Database Syst Rev 2021; 5:CD012776.</a></li><li><a class="nounderline abstract_t">Staedke SG, Gonahasa S, Dorsey G, et al. Effect of long-lasting insecticidal nets with and without piperonyl butoxide on malaria indicators in Uganda (LLINEUP): a pragmatic, cluster-randomised trial embedded in a national LLIN distribution campaign. Lancet 2020; 395:1292.</a></li><li><a class="nounderline abstract_t">Protopopoff N, Mosha JF, Lukole E, et al. Effectiveness of a long-lasting piperonyl butoxide-treated insecticidal net and indoor residual spray interventions, separately and together, against malaria transmitted by pyrethroid-resistant mosquitoes: a cluster, randomised controlled, two-by-two factorial design trial. Lancet 2018; 391:1577.</a></li><li><a class="nounderline abstract_t">Mosha JF, Kulkarni MA, Lukole E, et al. Effectiveness and cost-effectiveness against malaria of three types of dual-active-ingredient long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs in Tanzania: a four-arm, cluster-randomised trial. Lancet 2022; 399:1227.</a></li><li><a class="nounderline abstract_t">Accrombessi M, Cook J, Dangbenon E, et al. Efficacy of pyriproxyfen-pyrethroid long-lasting insecticidal nets (LLINs) and chlorfenapyr-pyrethroid LLINs compared with pyrethroid-only LLINs for malaria control in Benin: a cluster-randomised, superiority trial. Lancet 2023; 401:435.</a></li><li><a class="nounderline abstract_t">Tiono AB, Ouédraogo A, Ouattara D, et al. Efficacy of Olyset Duo, a bednet containing pyriproxyfen and permethrin, versus a permethrin-only net against clinical malaria in an area with highly pyrethroid-resistant vectors in rural Burkina Faso: a cluster-randomised controlled trial. Lancet 2018; 392:569.</a></li><li><a class="nounderline abstract_t">Lindsay SW, Thomas MB, Kleinschmidt I. Threats to the effectiveness of insecticide-treated bednets for malaria control: thinking beyond insecticide resistance. Lancet Glob Health 2021; 9:e1325.</a></li><li><a class="nounderline abstract_t">Fink G, Mrema S, Abdulla S, et al. Mosquito Net Use in Early Childhood and Survival to Adulthood in Tanzania. N Engl J Med 2022; 386:428.</a></li><li><a class="nounderline abstract_t">Pryce J, Medley N, Choi L. Indoor residual spraying for preventing malaria in communities using insecticide-treated nets. Cochrane Database Syst Rev 2022; 1:CD012688.</a></li><li class="breakAll">World Health Organization. WHO guidelines for malaria - 16 October 2023. https://app.magicapp.org/#/guideline/7661 (Accessed on November 06, 2023).</li><li class="breakAll">The Plus Project. https://www.psi.org/project/plusproject/ (Accessed on November 06, 2023).</li><li><a class="nounderline abstract_t">Crawley J, Sismanidis C, Goodman T, et al. Effect of intermittent preventive treatment for malaria during infancy on serological responses to measles and other vaccines used in the Expanded Programme on Immunization: results from five randomised controlled trials. Lancet 2012; 380:1001.</a></li><li><a class="nounderline abstract_t">Esu EB, Oringanje C, Meremikwu MM. Intermittent preventive treatment for malaria in infants. Cochrane Database Syst Rev 2021; 7:CD011525.</a></li><li><a class="nounderline abstract_t">ACCESS-SMC Partnership. Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study. Lancet 2020; 396:1829.</a></li><li><a class="nounderline abstract_t">Meremikwu MM, Donegan S, Sinclair D, et al. Intermittent preventive treatment for malaria in children living in areas with seasonal transmission. Cochrane Database Syst Rev 2012; :CD003756.</a></li><li><a class="nounderline abstract_t">Cissé B, Ba EH, Sokhna C, et al. Effectiveness of Seasonal Malaria Chemoprevention in Children under Ten Years of Age in Senegal: A Stepped-Wedge Cluster-Randomised Trial. PLoS Med 2016; 13:e1002175.</a></li><li><a class="nounderline abstract_t">Chandramohan D, Dicko A, Zongo I, et al. Effect of Adding Azithromycin to Seasonal Malaria Chemoprevention. N Engl J Med 2019; 380:2197.</a></li><li><a class="nounderline abstract_t">Nankabirwa JI, Wandera B, Amuge P, et al. Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial. Clin Infect Dis 2014; 58:1404.</a></li><li><a class="nounderline abstract_t">Athuman M, Kabanywanyi AM, Rohwer AC. Intermittent preventive antimalarial treatment for children with anaemia. Cochrane Database Syst Rev 2015; 1:CD010767.</a></li><li><a class="nounderline abstract_t">Portugal S, Tran TM, Ongoiba A, et al. Treatment of Chronic Asymptomatic Plasmodium falciparum Infection Does Not Increase the Risk of Clinical Malaria Upon Reinfection. Clin Infect Dis 2017; 64:645.</a></li><li><a class="nounderline abstract_t">Boyce RM, Hollingsworth BD, Baguma E, et al. Dihydroartemisinin-Piperaquine Chemoprevention and Malaria Incidence After Severe Flooding: Evaluation of a Pragmatic Intervention in Rural Uganda. Clin Infect Dis 2022; 74:2191.</a></li><li class="breakAll">World Health Organization, United Nations Children’s Fund. Cotrimoxazole prophylaxis for HIV-exposed and HIV-infected infants and children: practical approaches to implementation and scale up. Geneva, Switzerland: WHO/UNICEF, 2009.</li><li><a class="nounderline abstract_t">Davis NL, Barnett EJ, Miller WC, et al. Impact of daily cotrimoxazole on clinical malaria and asymptomatic parasitemias in HIV-exposed, uninfected infants. Clin Infect Dis 2015; 61:368.</a></li><li><a class="nounderline abstract_t">Chintu C, Bhat GJ, Walker AS, et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 2004; 364:1865.</a></li><li class="breakAll">World Health Organization. Chemotherapy of malaria. Geneva, Switzerland, 2015.</li><li><a class="nounderline abstract_t">Mermin J, Lule J, Ekwaru JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004; 364:1428.</a></li><li><a class="nounderline abstract_t">Mermin J, Ekwaru JP, Liechty CA, et al. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet 2006; 367:1256.</a></li><li><a class="nounderline abstract_t">Kamya MR, Gasasira AF, Achan J, et al. Effects of trimethoprim-sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. AIDS 2007; 21:2059.</a></li><li><a class="nounderline abstract_t">Walker AS, Ford D, Gilks CF, et al. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet 2010; 375:1278.</a></li><li><a class="nounderline abstract_t">Campbell JD, Moore D, Degerman R, et al. HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts &gt;200 cells/μL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea. Clin Infect Dis 2012; 54:1204.</a></li><li><a class="nounderline abstract_t">Eisele TP. Mass drug administration can be a valuable addition to the malaria elimination toolbox. Malar J 2019; 18:281.</a></li><li><a class="nounderline abstract_t">Eisele TP, Bennett A, Silumbe K, et al. Short-term Impact of Mass Drug Administration With Dihydroartemisinin Plus Piperaquine on Malaria in Southern Province Zambia: A Cluster-Randomized Controlled Trial. J Infect Dis 2016; 214:1831.</a></li><li><a class="nounderline abstract_t">Shah MP, Hwang J, Choi L, et al. Mass drug administration for malaria. Cochrane Database Syst Rev 2021; 9:CD008846.</a></li><li><a class="nounderline abstract_t">Landier J, Parker DM, Thu AM, et al. Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme. Lancet 2018; 391:1916.</a></li><li><a class="nounderline abstract_t">Mwesigwa J, Achan J, Affara M, et al. Mass Drug Administration With Dihydroartemisinin-piperaquine and Malaria Transmission Dynamics in The Gambia: A Prospective Cohort Study. Clin Infect Dis 2019; 69:278.</a></li><li><a class="nounderline abstract_t">Björkman A, Cook J, Sturrock H, et al. Spatial Distribution of Falciparum Malaria Infections in Zanzibar: Implications for Focal Drug Administration Strategies Targeting Asymptomatic Parasite Carriers. Clin Infect Dis 2017; 64:1236.</a></li><li><a class="nounderline abstract_t">Tripura R, Peto TJ, Chea N, et al. A Controlled Trial of Mass Drug Administration to Interrupt Transmission of Multidrug-Resistant Falciparum Malaria in Cambodian Villages. Clin Infect Dis 2018; 67:817.</a></li><li><a class="nounderline abstract_t">Sutanto I, Kosasih A, Elyazar IRF, et al. Negligible Impact of Mass Screening and Treatment on Mesoendemic Malaria Transmission at West Timor in Eastern Indonesia: A Cluster-Randomized Trial. Clin Infect Dis 2018; 67:1364.</a></li><li><a class="nounderline abstract_t">Hsiang MS, Ntuku H, Roberts KW, et al. Effectiveness of reactive focal mass drug administration and reactive focal vector control to reduce malaria transmission in the low malaria-endemic setting of Namibia: a cluster-randomised controlled, open-label, two-by-two factorial design trial. Lancet 2020; 395:1361.</a></li><li><a class="nounderline abstract_t">Chaccour CJ, Kobylinski KC, Bassat Q, et al. Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination. Malar J 2013; 12:153.</a></li><li><a class="nounderline abstract_t">Foy BD, Alout H, Seaman JA, et al. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. Lancet 2019; 393:1517.</a></li><li><a class="nounderline abstract_t">Smit MR, Ochomo EO, Aljayyoussi G, et al. Human Direct Skin Feeding Versus Membrane Feeding to Assess the Mosquitocidal Efficacy of High-Dose Ivermectin (IVERMAL Trial). Clin Infect Dis 2019; 69:1112.</a></li><li><a class="nounderline abstract_t">Abdulla S, Oberholzer R, Juma O, et al. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med 2008; 359:2533.</a></li><li><a class="nounderline abstract_t">Breman JG, Plowe CV. A malaria vaccine for control: more progress. J Infect Dis 2009; 200:317.</a></li><li class="breakAll">World Health Organization. Malaria vaccine implementation programme. https://www.who.int/initiatives/malaria-vaccine-implementation-programme (Accessed on October 06, 2021).</li><li><a class="nounderline abstract_t">Agnandji ST, Asante KP, Lyimo J, et al. Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. J Infect Dis 2010; 202:1076.</a></li><li><a class="nounderline abstract_t">RTS,S Clinical Trials Partnership, Agnandji ST, Lell B, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011; 365:1863.</a></li><li><a class="nounderline abstract_t">RTS,S Clinical Trials Partnership, Agnandji ST, Lell B, et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012; 367:2284.</a></li><li><a class="nounderline abstract_t">Olotu A, Fegan G, Wambua J, et al. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N Engl J Med 2013; 368:1111.</a></li><li><a class="nounderline abstract_t">Bejon P, White MT, Olotu A, et al. Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data. Lancet Infect Dis 2013; 13:319.</a></li><li><a class="nounderline abstract_t">RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015; 386:31.</a></li><li><a class="nounderline abstract_t">Bejon P, Lusingu J, Olotu A, et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008; 359:2521.</a></li><li><a class="nounderline abstract_t">Olotu A, Fegan G, Wambua J, et al. Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children. N Engl J Med 2016; 374:2519.</a></li><li><a class="nounderline abstract_t">Neafsey DE, Juraska M, Bedford T, et al. Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. N Engl J Med 2015; 373:2025.</a></li><li class="breakAll">WHO recommends R21/Matrix-M vaccine for malaria prevention in updated advice on immunization. World Health Organization, 2023. Available at: https://www.who.int/news/item/02-10-2023-who-recommends-r21-matrix-m-vaccine-for-malaria-prevention-in-updated-advice-on-immunization (Accessed on October 06, 2023).</li><li class="breakAll">https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4584076 (Accessed on October 06, 2023).</li><li><a class="nounderline abstract_t">Datoo MS, Natama MH, Somé A, et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet 2021; 397:1809.</a></li><li><a class="nounderline abstract_t">Wu RL, Idris AH, Berkowitz NM, et al. Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria. N Engl J Med 2022; 387:397.</a></li><li><a class="nounderline abstract_t">Kayentao K, Ongoiba A, Preston AC, et al. Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali. N Engl J Med 2022; 387:1833.</a></li><li><a class="nounderline abstract_t">Hamon J. Les moustiques anthropophiles de la région de Bobo Dioulasso: cycles d'aggressivité et variations saisonnières. Annales de la Societé d'Entomologie de la France 1963; 132:85.</a></li><li><a class="nounderline abstract_t">Pates H, Curtis C. Mosquito behavior and vector control. Annu Rev Entomol 2005; 50:53.</a></li><li class="breakAll">Curtis CF. Integrated vector management for malaria. In: Integrated Pest Management, Radcliffe E (Ed), Cambridge University Press, Cambridge 2008.</li><li><a class="nounderline abstract_t">Rowland M, Mohammed N, Rehman H, et al. Anopheline vectors and malaria transmission in eastern Afghanistan. Trans R Soc Trop Med Hyg 2002; 96:620.</a></li><li><a class="nounderline abstract_t">Van Bortel W, Trung HD, Thuan le K, et al. The insecticide resistance status of malaria vectors in the Mekong region. Malar J 2008; 7:102.</a></li><li><a class="nounderline abstract_t">Chandre F, Darrier F, Manga L, et al. Status of pyrethroid resistance in Anopheles gambiae sensu lato. Bull World Health Organ 1999; 77:230.</a></li><li class="breakAll">Clements AN. The Biology of Mosquitoes, Chapman and Hall, 1992. Vol Volume 1.</li><li class="breakAll">World Health Organization. Manual for indoor residual spraying application of residual sprays for vector control. WHO/CDS/WHOPES/GCDPP/2000.3 Rev.1.</li><li><a class="nounderline abstract_t">Sadasivaiah S, Tozan Y, Breman JG. Dichlorodiphenyltrichloroethane (DDT) for indoor residual spraying in Africa: how can it be used for malaria control? Am J Trop Med Hyg 2007; 77:249.</a></li><li><a class="nounderline abstract_t">Roberts DR, Alecrim WD. Behavioral response of Anopheles darlingi to DDT-sprayed house walls in Amazonia. Bull Pan Am Health Organ 1991; 25:210.</a></li><li class="breakAll">MacDonald G. Epidemiology and Control of Malaria, Oxford University Press, London 1957.</li><li><a class="nounderline abstract_t">Giglioli G. Changes in the pattern of mortality following the eradication of hyperendemic malaria from a highly susceptible community. Bull World Health Organ 1972; 46:181.</a></li><li><a class="nounderline abstract_t">Maharaj R, Mthembu DJ, Sharp BL. Impact of DDT re-introduction on malaria transmission in KwaZulu-Natal. S Afr Med J 2005; 95:871.</a></li><li><a class="nounderline abstract_t">Katureebe A, Zinszer K, Arinaitwe E, et al. Measures of Malaria Burden after Long-Lasting Insecticidal Net Distribution and Indoor Residual Spraying at Three Sites in Uganda: A Prospective Observational Study. PLoS Med 2016; 13:e1002167.</a></li><li><a class="nounderline abstract_t">Raouf S, Mpimbaza A, Kigozi R, et al. Resurgence of Malaria Following Discontinuation of Indoor Residual Spraying of Insecticide in an Area of Uganda With Previously High-Transmission Intensity. Clin Infect Dis 2017; 65:453.</a></li><li><a class="nounderline abstract_t">Nankabirwa JI, Briggs J, Rek J, et al. Persistent Parasitemia Despite Dramatic Reduction in Malaria Incidence After 3 Rounds of Indoor Residual Spraying in Tororo, Uganda. J Infect Dis 2019; 219:1104.</a></li><li><a class="nounderline abstract_t">Zinszer K, Charland K, Vahey S, et al. The Impact of Multiple Rounds of Indoor Residual Spraying on Malaria Incidence and Hemoglobin Levels in a High-Transmission Setting. J Infect Dis 2020; 221:304.</a></li><li><a class="nounderline abstract_t">Bath D, Cook J, Govere J, et al. Effectiveness and cost-effectiveness of reactive, targeted indoor residual spraying for malaria control in low-transmission settings: a cluster-randomised, non-inferiority trial in South Africa. Lancet 2021; 397:816.</a></li><li><a class="nounderline abstract_t">Sternberg ED, Cook J, Alou LPA, et al. Impact and cost-effectiveness of a lethal house lure against malaria transmission in central Côte d'Ivoire: a two-arm, cluster-randomised controlled trial. Lancet 2021; 397:805.</a></li><li class="breakAll">World Health Organization. Vector alert: Anopheles stephensi invasion and spread in Africa and Sri Lanka. https://iris.who.int/bitstream/handle/10665/365710/9789240067714-eng.pdf?sequence=1&amp;isAllowed=y (Accessed on November 06, 2023).</li><li><a class="nounderline abstract_t">Walshe DP, Garner P, Adeel AA, et al. Larvivorous fish for preventing malaria transmission. Cochrane Database Syst Rev 2017; 12:CD008090.</a></li><li><a class="nounderline abstract_t">Ghosh SK, Tiwari SN, Sathyanarayan TS, et al. Larvivorous fish in wells target the malaria vector sibling species of the Anopheles culicifacies complex in villages in Karnataka, India. Trans R Soc Trop Med Hyg 2005; 99:101.</a></li><li><a class="nounderline abstract_t">Yapabandara AM, Curtis CF, Wickramasinghe MB, Fernando WP. Control of malaria vectors with the insect growth regulator pyriproxyfen in a gem-mining area in Sri Lanka. Acta Trop 2001; 80:265.</a></li><li><a class="nounderline abstract_t">Fillinger U, Lindsay SW. Suppression of exposure to malaria vectors by an order of magnitude using microbial larvicides in rural Kenya. Trop Med Int Health 2006; 11:1629.</a></li><li><a class="nounderline abstract_t">Andreasen MH, Curtis CF. Optimal life stage for radiation sterilization of Anopheles males and their fitness for release. Med Vet Entomol 2005; 19:238.</a></li><li class="breakAll">Klassen W, Curtis CF. History of the Sterile Insect Technique (SIT). In: The Sterile Insect Technique: Principles and Practice in Area-wide Integrated Pest Management, Dyck VA, Hendrichs L, Robinson AS (Eds), Springer, Heidelberg, Germany 2005. p.3.</li><li><a class="nounderline abstract_t">Catteruccia F, Benton JP, Crisanti A. An Anopheles transgenic sexing strain for vector control. Nat Biotechnol 2005; 23:1414.</a></li><li><a class="nounderline abstract_t">Ito J, Ghosh A, Moreira LA, et al. Transgenic anopheline mosquitoes impaired in transmission of a malaria parasite. Nature 2002; 417:452.</a></li><li><a class="nounderline abstract_t">Chen CH, Huang H, Ward CM, et al. A synthetic maternal-effect selfish genetic element drives population replacement in Drosophila. Science 2007; 316:597.</a></li><li class="breakAll">Burt A, Trivers R. Genes in Conflict, Belknap Press, Harvard University, 2006.</li><li class="breakAll">Curtis CF, Coleman PG, Kelly D. Advantages and limitations of transgenic vector control: sterile males versus gene drivers. In: Genetically Modified Mosquitoes for Malaria Control, Boete C (Ed), Landes Bioscience, Georgetown, Texas 2006. p.60.</li><li class="breakAll">World Health Organization. World Malaria Report 2018. https://apps.who.int/iris/handle/10665/275867 (Accessed on August 11, 2021).</li></ol></div><div id="topicVersionRevision">Topic 5702 Version 96.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.who.int/publications/i/item/guidelines-for-malaria" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : World Health Organization. WHO Guidelines for malaria 2022, 15 November 2022. https://www.who.int/publications/i/item/guidelines-for-malaria (Accessed on April 01, 2022).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2022" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : World Health Organization. World malaria report 2022. https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2022 (Accessed on November 06, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2021" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : World Health Organization. World malaria report 2021. https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2021 (Accessed on February 07, 2022).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.who.int/publications/i/item/9789240060265" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : World Health Organization. Strategy to respond to antimalarial drug resistance in Africa. https://www.who.int/publications/i/item/9789240060265 (Accessed on November 06, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.gavi.org/vaccineswork/hope-spreads-18-million-doses-first-malaria-vaccine-are-allocated#:~:text=These%2018%20million%20first%20doses,for%20the%20period%202023%2D2025" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Mwaniki M, Prabhu M. Hope spreads as 18 million doses of the first malaria vaccine are allocated to 12 African countries. Gavi, the Vaccine Alliance. https://www.gavi.org/vaccineswork/hope-spreads-18-million-doses-first-malaria-vaccine-are-allocated#:~:text=These%2018%20million%20first%20doses,for%20the%20period%202023%2D2025. (Accessed on November 06, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.who.int/teams/global-malaria-programme/elimination/countries-and-territories-certified-malaria-free-by-who" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : World Health Organization. Countries and territories certified malaria-free by WHO. Global Malaria Programme. https://www.who.int/teams/global-malaria-programme/elimination/countries-and-territories-certified-malaria-free-by-who (Accessed on November 06, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23463635" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Transfusion-transmitted malaria in Ghana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28575383" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : On Taking a Different Route: An Unlikely Case of Malaria by Nosocomial Transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33735166" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Malaria Surveillance - United States, 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16931811" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Relationship between the entomologic inoculation rate and the force of infection for Plasmodium falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16931811" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Relationship between the entomologic inoculation rate and the force of infection for Plasmodium falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16931811" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Relationship between the entomologic inoculation rate and the force of infection for Plasmodium falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16931811" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Relationship between the entomologic inoculation rate and the force of infection for Plasmodium falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15331828" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A review of the clinical and epidemiologic burdens of epidemic malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36048717" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Malaria Surveillance - United States, 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37676839" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Outbreak of Locally Acquired Mosquito-Transmitted (Autochthonous) Malaria - Florida and Texas, May-July 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37676839" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Outbreak of Locally Acquired Mosquito-Transmitted (Autochthonous) Malaria - Florida and Texas, May-July 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37676839" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Outbreak of Locally Acquired Mosquito-Transmitted (Autochthonous) Malaria - Florida and Texas, May-July 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18303939" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15759000" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The global distribution of clinical episodes of Plasmodium falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18165478" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Vivax malaria: neglected and not benign.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19544698" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Eradicating malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18171246" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Plasmodium knowlesi: the fifth human malaria parasite.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37263994" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : No evidence of sustained nonzoonotic Plasmodium knowlesi transmission in Malaysia from modelling malaria case data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33870436" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Plasmodium simium: Population Genomics Reveals the Origin of a Reverse Zoonosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33870436" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Plasmodium simium: Population Genomics Reveals the Origin of a Reverse Zoonosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18165473" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Malaria surveillance counts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21311588" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A research agenda for malaria eradication: health systems and operational research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24559537" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The changing risk of Plasmodium falciparum malaria infection in Africa: 2000-10: a spatial and temporal analysis of transmission intensity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24559538" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Malaria control in Africa: progress but still much to do.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26375008" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27723434" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Mapping Plasmodium falciparum Mortality in Africa between 1990 and 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22632187" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30860016" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Falsified and Substandard Drugs: Stopping the Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19478249" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Effect of malaria rapid diagnostic tests on the management of uncomplicated malaria with artemether-lumefantrine in Kenya: a cluster randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11425172" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21311579" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A research agenda to underpin malaria eradication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29190300" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : malERA: An updated research agenda for malaria elimination and eradication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29190300" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : malERA: An updated research agenda for malaria elimination and eradication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29190300" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : malERA: An updated research agenda for malaria elimination and eradication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34432975" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34432975" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17940319" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Plant based insect repellent and insecticide treated bed nets to protect against malaria in areas of early evening biting vectors: double blind randomised placebo controlled clinical trial in the Bolivian Amazon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14996362" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : DEET mosquito repellent provides personal protection against malaria: a household randomized trial in an Afghan refugee camp in Pakistan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30398672" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Insecticide-treated nets for preventing malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30398672" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Insecticide-treated nets for preventing malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21856232" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Malaria morbidity and pyrethroid resistance after the introduction of insecticide-treated bednets and artemisinin-based combination therapies: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22709930" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Loss of household protection from use of insecticide-treated nets against pyrethroid-resistant mosquitoes, benin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9735932" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A comparison of use of a pyrethroid either for house spraying or for bednet treatment against malaria vectors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26880124" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Averting a malaria disaster: will insecticide resistance derail malaria control?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16282294" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Protective efficacy of lambda-cyhalothrin treated nets in Anopheles gambiae pyrethroid resistance areas of Côte d'Ivoire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30488945" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34027998" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32305094" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Effect of long-lasting insecticidal nets with and without piperonyl butoxide on malaria indicators in Uganda (LLINEUP): a pragmatic, cluster-randomised trial embedded in a national LLIN distribution campaign.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29655496" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Effectiveness of a long-lasting piperonyl butoxide-treated insecticidal net and indoor residual spray interventions, separately and together, against malaria transmitted by pyrethroid-resistant mosquitoes: a cluster, randomised controlled, two-by-two factorial design trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35339225" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effectiveness and cost-effectiveness against malaria of three types of dual-active-ingredient long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs in Tanzania: a four-arm, cluster-randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36706778" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Efficacy of pyriproxyfen-pyrethroid long-lasting insecticidal nets (LLINs) and chlorfenapyr-pyrethroid LLINs compared with pyrethroid-only LLINs for malaria control in Benin: a cluster-randomised, superiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30104047" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Efficacy of Olyset Duo, a bednet containing pyriproxyfen and permethrin, versus a permethrin-only net against clinical malaria in an area with highly pyrethroid-resistant vectors in rural Burkina Faso: a cluster-randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34216565" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Threats to the effectiveness of insecticide-treated bednets for malaria control: thinking beyond insecticide resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35108469" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Mosquito Net Use in Early Childhood and Survival to Adulthood in Tanzania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35038163" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Indoor residual spraying for preventing malaria in communities using insecticide-treated nets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35038163" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Indoor residual spraying for preventing malaria in communities using insecticide-treated nets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35038163" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Indoor residual spraying for preventing malaria in communities using insecticide-treated nets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22850358" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Effect of intermittent preventive treatment for malaria during infancy on serological responses to measles and other vaccines used in the Expanded Programme on Immunization: results from five randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34273901" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Intermittent preventive treatment for malaria in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33278936" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22336792" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Intermittent preventive treatment for malaria in children living in areas with seasonal transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27875528" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Effectiveness of Seasonal Malaria Chemoprevention in Children under Ten Years of Age in Senegal: A Stepped-Wedge Cluster-Randomised Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30699301" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effect of Adding Azithromycin to Seasonal Malaria Chemoprevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24621953" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25582096" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Intermittent preventive antimalarial treatment for children with anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28362910" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Treatment of Chronic Asymptomatic Plasmodium falciparum Infection Does Not Increase the Risk of Clinical Malaria Upon Reinfection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34499116" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Dihydroartemisinin-Piperaquine Chemoprevention and Malaria Incidence After Severe Flooding: Evaluation of a Pragmatic Intervention in Rural Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34499116" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Dihydroartemisinin-Piperaquine Chemoprevention and Malaria Incidence After Severe Flooding: Evaluation of a Pragmatic Intervention in Rural Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25900173" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Impact of daily cotrimoxazole on clinical malaria and asymptomatic parasitemias in HIV-exposed, uninfected infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15555666" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15555666" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15488218" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16631881" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17885296" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Effects of trimethoprim-sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20347483" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22423133" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts&gt;200 cells/μL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31438950" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Mass drug administration can be a valuable addition to the malaria elimination toolbox.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27923947" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Short-term Impact of Mass Drug Administration With Dihydroartemisinin Plus Piperaquine on Malaria in Southern Province Zambia: A Cluster-Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34585740" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Mass drug administration for malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29703425" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30304511" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Mass Drug Administration With Dihydroartemisinin-piperaquine and Malaria Transmission Dynamics in The Gambia: A Prospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28431115" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Spatial Distribution of Falciparum Malaria Infections in Zanzibar: Implications for Focal Drug Administration Strategies Targeting Asymptomatic Parasite Carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29522113" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : A Controlled Trial of Mass Drug Administration to Interrupt Transmission of Multidrug-Resistant Falciparum Malaria in Cambodian Villages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29579195" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Negligible Impact of Mass Screening and Treatment on Mesoendemic Malaria Transmission at West Timor in Eastern Indonesia: A Cluster-Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32334702" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Effectiveness of reactive focal mass drug administration and reactive focal vector control to reduce malaria transmission in the low malaria-endemic setting of Namibia: a cluster-randomised controlled, open-label, two-by-two factorial design trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23647969" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30878222" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30590537" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Human Direct Skin Feeding Versus Membrane Feeding to Assess the Mosquitocidal Efficacy of High-Dose Ivermectin (IVERMAL Trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19064623" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19569963" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : A malaria vaccine for control: more progress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19569963" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : A malaria vaccine for control: more progress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20735271" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22007715" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23136909" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23514288" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23454164" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25913272" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19064627" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27355532" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26488565" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26488565" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26488565" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33964223" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35921449" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36317783" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Les moustiques anthropophiles de la région de Bobo Dioulasso: cycles d'aggressivitéet variations saisonnières</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15355233" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Mosquito behavior and vector control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15355233" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Mosquito behavior and vector control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12625136" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Anopheline vectors and malaria transmission in eastern Afghanistan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18534006" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : The insecticide resistance status of malaria vectors in the Mekong region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10212513" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Status of pyrethroid resistance in Anopheles gambiae sensu lato.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10212513" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Status of pyrethroid resistance in Anopheles gambiae sensu lato.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10212513" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Status of pyrethroid resistance in Anopheles gambiae sensu lato.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18165500" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Dichlorodiphenyltrichloroethane (DDT) for indoor residual spraying in Africa: how can it be used for malaria control?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1742567" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Behavioral response of Anopheles darlingi to DDT-sprayed house walls in Amazonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1742567" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Behavioral response of Anopheles darlingi to DDT-sprayed house walls in Amazonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4624339" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Changes in the pattern of mortality following the eradication of hyperendemic malaria from a highly susceptible community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16344885" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Impact of DDT re-introduction on malaria transmission in KwaZulu-Natal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27824885" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Measures of Malaria Burden after Long-Lasting Insecticidal Net Distribution and Indoor Residual Spraying at Three Sites in Uganda: A Prospective Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28369387" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Resurgence of Malaria Following Discontinuation of Indoor Residual Spraying of Insecticide in an Area of Uganda With Previously High-Transmission Intensity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30383230" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Persistent Parasitemia Despite Dramatic Reduction in Malaria Incidence After 3 Rounds of Indoor Residual Spraying in Tororo, Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31599325" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : The Impact of Multiple Rounds of Indoor Residual Spraying on Malaria Incidence and Hemoglobin Levels in a High-Transmission Setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33640068" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Effectiveness and cost-effectiveness of reactive, targeted indoor residual spraying for malaria control in low-transmission settings: a cluster-randomised, non-inferiority trial in South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33640067" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Impact and cost-effectiveness of a lethal house lure against malaria transmission in central Côte d'Ivoire: a two-arm, cluster-randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33640067" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Impact and cost-effectiveness of a lethal house lure against malaria transmission in central Côte d'Ivoire: a two-arm, cluster-randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29226959" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Larvivorous fish for preventing malaria transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15607336" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Larvivorous fish in wells target the malaria vector sibling species of the Anopheles culicifacies complex in villages in Karnataka, India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11700185" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Control of malaria vectors with the insect growth regulator pyriproxyfen in a gem-mining area in Sri Lanka.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17054742" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Suppression of exposure to malaria vectors by an order of magnitude using microbial larvicides in rural Kenya.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16134971" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Optimal life stage for radiation sterilization of Anopheles males and their fitness for release.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16134971" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Optimal life stage for radiation sterilization of Anopheles males and their fitness for release.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16244659" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : An Anopheles transgenic sexing strain for vector control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12024215" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Transgenic anopheline mosquitoes impaired in transmission of a malaria parasite.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17395794" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : A synthetic maternal-effect selfish genetic element drives population replacement in Drosophila.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
